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The incidence of aneurysmal subarach-
noid hemorrhage in Finland is among 
the highest in the world, affecting ap-
proximately 1200 patients each year. 
Endovascular treatment of intracranial 
aneurysms is firmly established, but 
endosaccular coil embolization of very 
wide-necked or otherwise complex 
cerebral aneurysms is often technically 
challenging. The development of in-
tracranial stents has revolutionized the 
endovascular management of complex 
intracranial aneurysms and many previ-
ously untreatable cerebral aneurysms 
are now within the scope of endovas-
cular treatment. However, many limita-
tions and challenges still persist and the 
optimal treatment of cerebral aneurysms 
requires complementary interaction of 
surgical and endovascular techniques.
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ABSTRACT 
 
Endosaccular coil embolization was introduced in 1991 as an alternative, minimally invasive 
approach in the treatment of cerebral aneurysms. The embolization system consists of a 
microcatheter which is transarterially delivered into the aneurysm and a very soft and 
flexible platinum coil which is detached from the delivery wire into the aneurysm sac, thus 
promoting aneurysm thrombosis and exclusion of the aneurysm from the circulation. Coil 
embolization of very wide-necked or otherwise complex cerebral aneurysms is, however, 
often technically challenging since the coils may protrude from the aneurysm into the 
parent artery. Intracranial stents, initially launched in 2002, were developed to provide 
additional support and remodeling of the aneurysm neck, and the concept of parent artery 
reconstruction was further advanced with flow-diverting stents introduced in 2008. 
The development of intracranial stents has revolutionized the endovascular management 
of complex intracranial aneurysms and the proportion of aneurysms allocated to 
endovascular therapy ranges from 10 % to 90 %. Many previously untreatable cerebral 
aneurysms (i.e. fusiform or dissecting aneurysms or aneurysms with a wide-necked profile) 
are now within the scope of endovascular treatment, but many limitations remain. Our 
knowledge of the effectivity and safety of advanced endovascular techniques is often 
insufficient and the treatment options are still far from comprehensive. The aim of this 
thesis was to evaluate the feasibility and safety of stent-assisted embolization in the 
treatment of recurrent or residual cerebral aneurysms, stent-assisted embolization of acutely 
ruptured wide necked cerebral aneurysms, and the applicability of flow-diverting stents in 
the endovascular therapy of complex intracranial aneurysms. 
This study is based on the patients with intracranial aneurysms treated with either stent-
assisted embolization or with a flow-diverting stent in Kuopio University Hospital, 
Tampere University Hospital, and Turku University Hospital during the study period from 
February 2003 to June 2011. In the case of recurrent aneurysms, the initial coil embolization 
or surgical ligation of the aneurysm had been performed between October 1997 and July 
2008. In addition to evaluating the technical success of the procedure, angiographic and 
clinical outcomes were retrospectively assessed. Special attention was focused on the 
procedure-related complications and in finding factors associated with poor clinical 
outcome. 
Stent-assisted coil embolization is a feasible endovascular treatment method for ruptured 
wide-necked intracranial aneurysms which are difficult to treat surgically or with balloon-
assisted embolization also during acute SAH. Stent-assisted embolization is beneficial also 
for the treatment of wide-necked recurrent or residual intracranial aneurysms, although 
stability and permanent occlusion of the aneurysm is unlikely if the aneurysm exceeds 
20 mm in diameter, the recurrent diameter of the aneurysm exceeds 10 mm, or if mass effect 
is present with the recurrent aneurysm. Flow-diverting stents, on the other hand, offer 
another valuable tool in the endovascular treatment of complex cerebral aneurysms. Many 
previously untreatable aneurysms may be successfully treated with a flow-diverting stent, 
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but the associated risk of thromboembolic events is justifiable only if conventional 
endovascular or surgical treatment options are not applicable.  
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TIIVISTELMÄ 
 
Ensimmäiset aivovaltimoaneurysmien embolisaatiohoidot tehtiin 1990-luvun alussa 
viemällä aneurysman sisälle mikrokatetrin kautta platinakoileja, jotka verenvirtauksen 
uudelleenohjautumisen ja hyytymisjärjestelmän aktivoitumisen kautta sulkevat 
aneurysman verenkierrosta. Hyvin leveäkantaisten tai muutoin kompleksien 
aivovaltimoaneurysmien suonensisäinen embolisaatiohoito on kuitenkin usein haastavaa, 
sillä koilit saattavat pyrkiä työntymään ulos aneurysmasäkistä. Tämän ehkäisemiseksi 
kehitetyt verkkoproteesit eli stentit tulivat markkinoille vuonna 2002 ja vuonna 2008 
esiteltiin ensimmäiset verenvirtauksen uudelleenohjautumiseen perustuvat ns. flow 
diverting -stentit. 
Stenttien nopea kehittyminen on mullistanut aivovaltimoaneurysmien suonensisäisen 
hoidon ja keskusten hoitokäytännöistä riippuen 10–90 % kaikista aivovaltimoaneurysmista 
voidaan nykyisin hoitaa suonensisäisesti. Hoitomenetelmissä on kuitenkin edelleen useita 
rajoitteita ja tiedot uusien suonensisäisten hoitomenetelmien vaikuttavuudesta ja 
turvallisuudesta ovat lisäksi puutteellisia. Tämän tutkimuksen tarkoitus on selvittää 
stenttiavusteisen embolisaatiohoiton vaikuttavuutta ja turvallisuutta uusiutuneiden ja 
jäännösaneurysmien sekä puhjenneiden leveäkantaisten aivovaltimoaneurysmien hoidossa 
sekä toisaalta uusien verenvirtauksen uudelleenohjautumiseen perustuvien stenttien (ns. 
flow diverting -stenttien) käytettävyyttä kompleksien aivovaltimoaneurysmien hoidossa. 
Tutkimusaineisto koostuu Kuopion yliopistollisessa sairaalassa, Tampereen 
yliopistollisessa sairaalassa sekä Turun yliopistollisessa sairaalassa helmikuun 2003 sekä 
kesäkuun 2011 välissä stenttiavusteisesti hoidetuista aivovaltimoaneurysmapotilaista, joista 
seulottiin kunkin osatyön mukainen tutkimuskohortti retrospektiivisessä asetelmassa. 
Uusiutuneiden aivovaltimoaneurysmien osalta aneurysmien primaarihoito oli toteutettu 
lokakuun 1997 ja heinäkuun 2008 välissä. Toimenpiteiden teknisen onnistumisen lisäksi 
tutkimuksessa arvioitiin hoitotuloksen pysyvyyttä sekä potilaiden kliinistä tilaa seuranta-
ajan puitteissa. Erityistä huomiota kiinnitettiin hoidon komplikaatioiden raportointiin ja 
komplikaatioille sekä hoidon epäonnistumiseen altistavien tekijöiden löytämiseen. 
Stenttiavusteinen embolisaatio on käyttökelpoinen hoitomenetelmä myös sellaisten 
puhjenneiden leveäkantaisten aivovaltimoaneurysmien hoidossa, jotka eivät sovellu 
kirurgiseen tai palloavusteiseen embolisaatiohoitoon. Stenttiavusteinen embolisaatio 
soveltuu myös uusiutuneiden sekä jäännösaneurysmien hoitoon joskin hyvän ja pysyvän 
hoitotuloksen saavuttaminen on epätodennäköistä mikäli aneurysma on läpimitaltaan yli 
20 mm, aneurysman rekanalisoitunut osa on läpimitaltaan yli 10 mm tai aneurysmaan 
liittyy massavaikutusta ympäröiviin rakenteisiin. Tutkimuksessa todettiin myös, että 
verenvirtauksen uudelleenohjautumiseen perustuvat flow diverting -stentit mahdollistavat 
useiden vaikeahoitoisten aivovaltimoaneurysmien hoidon, mutta toimenpiteeseen liittyvät, 
pääosin verihyytymien muodostumiseen liittyvät riskit ovat perusteltuja vain mikäli 
perinteiset suonensisäiset tai kirurgiset hoitomenetelmät eivät ole sovellettavissa 
aneurysman hoitamiseksi.  
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1 Introduction  
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating condition with 30-day 
mortality of up to 45 %, almost half of the survivors left disabled even with modern 
methods of diagnosis and treatment.1-6 Poor outcomes related to aSAH could theoretically 
be avoided by preventing the aneurysm rupture, which is the primary goal of aneurysm 
treatment. All of the treatment options are, however, associated with procedural risks and 
only a minority of the asymptomatic aneurysms will eventually rupture and cause aSAH. 
The risks associated with potential treatment methods should therefore be carefully 
evaluated and weighed against the estimated risk of aneurysm rupture prior to initiating 
aneurysm therapy. Endovascular therapy of cerebral aneurysms is firmly established, but 
the morphology of the aneurysm (i.e. large size and/or fusiform or wide-necked profile) 
may preclude conventional coil embolization of the aneurysm. Microsurgical treatment, 
either by aneurysm clipping or by bypass surgery possibly combined with parent vessel 
occlusion is often the primary treatment method of these complex cerebral aneurysms, but 
since the surgical treatment is also occasionally met with difficulties, a need for advanced 
endovascular techniques is established.7-13  
Intracranial stents have several theoretical advantages in the treatment of cerebral 
aneurysms. In addition to disturbing the inflow jet to the aneurysm sac and thus promoting 
aneurysm thrombosis, the presence of the stent reduces the risk of coil protrusion and 
provides a physical matrix for possible endothelial growth across the aneurysm neck. There 
are, however, also many limitations in stent-assisted coiling. The reconstruction of very 
wide-necked or fusiform aneurysms with coils may be difficult and even accessing the 
aneurysm sac after stenting may prove challenging, the dual antiplatelet therapy 
necessitated by the stent may be problematic especially in the setting of acute subarachnoid 
hemorrhage, and even when adequate occlusion has been initially achieved with stent-
assisted embolization, aneurysms remain prone to coil compaction and recanalization.  
Flow-diverting stents, on the other hand offer fascinating opportunities for the treatment 
of segmentally diseased vessels and complex cerebral aneurysms.14-19 The concept of flow 
redirection and curative vessel reconstruction represents a paradigm shift in the treatment 
philosophy for endovascular aneurysm therapy. However, many uncertainties remain with 
this relatively new form of aneurysm treatment, including i.a. the lack of long-term 
knowledge of the risk of arterial stenosis after stent deployment, the fate of perforating 
vessels crossed by the device, the duration of post-procedural antiplatelet medical therapy, 
and optimal patient selection.   
The rapidly developing and constantly changing field of endovascular aneurysm 
therapy offers an intriguing and fascinating field to investigate, the importance of which is 
accentuated by the knowledge that the incidence of aSAH in Finland is among the highest 
in the world, affecting approximately 1200 patients each year, often in the working age.20-22 
The treatment of intracranial aneurysms is challenging and advanced surgical and 
endovascular treatment methods are often complementary, emphasizing the role of 
multidisciplinary team approach in the treatment of intracranial aneurysms. 
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2  Review of the literature 
2.1  INTRACRANIAL ANEURYSMS 
An aneurysm is literally an abnormal focal dilatation of an artery (derived from the Greek 
word aneurýnein, to dilate).  Intracranial aneurysms are usually classified by their general 
phenotypic appearance into saccular and non-saccular aneurysms. While vast majority of 
cerebral aneurysms are saccular, pouch-like dilatations encountered predominantly in 
arterial bifurcations, other types of focal arterial dilatations (i.e. arterial dissecations, 
pseudoaneurysms, or fusiform arterial dilatations) are also often collectively called 
aneurysms, although they may have very little in common with saccular aneurysms. The 
terminology used to describe non-saccular aneurysms is also somewhat heterogenous. 
Some definitions are descriptive and based on the aneurysm morphology (i.e. fusiform, 
dolichoectatic), while others are related to the etiology of the aneurysm (i.e. dissecting or 
mycotic). Regardless of their etiology aneurysms form a focal discontinuity and a weak 
spot in the vessel wall, predisposing to aneurysm rupture, the most frequent cause of non-
traumatic subarachnoid hemorrhage (SAH).  
While aneurysmal SAH is the most common presentation of intracranial aneurysm 
rupture, the hemorrhage from an intracranial aneurysm may not be confined to the 
subarachnoid space but can also rupture into the brain parenchyma, the ventricular system, 
or rarely the subdural space.23,24 Unruptured cerebral aneurysms are usually asymptomatic, 
but they may cause symptoms (i.e. cranial nerve palsies or brain-stem compression 
symptoms) by exerting a mass effect to adjacent structures.25  
2.1.1  Epidemiology and risk factors 
The epidemiology of cerebral aneurysms differs to some extent from the epidemiology of 
aneurysmal SAH since most of the intracranial aneurysms never rupture and the annual 
risk of aneurysm rupture may be as low as 0.05 % in some aneurysms.26 The estimated 
prevalence of cerebral aneurysms varies considerably according to study design, study 
population, and aneurysm characteristics. Combining the data of autopsy and radiological 
studies, the prevalence of intracranial aneurysms is around 2 % (0.2–9 %) for adults without 
specific risk factors.24,26,27 
In a comprehensive systematic review of the literature, the prevalence of cerebral 
aneurysms was shown to be higher in patients with autosomal dominant polycystic kidney 
disease (relative risk [RR], 4.4), a familial predisposition (RR, 4.0), or systemic 
atherosclerotic vascular disease (RR, 2.3).26 The prevalence of intracranial aneurysms is ca. 
12 % in patients affected with polycystic kidney disease, 7 % in patients with fibromuscular 
dysplasia, and 5 % in patients with syndromic diseases of connective tissues (notably 
Ehlers-Danlos type IV).28 In addition to various connective tissue diseases, systemic 
inflammatory diseases (e.g. Takayasu arteritis, systemic lupus erythematosus, giant cell 
arteritis) may produce modifications of the arterial wall predisposing to aneurysm 
formation.5 Female gender seems to increase the risk for aneurysm formation, but does not 
affect the risk of aneurysm rupture to the same extent.29 It has also been suggested that 
smoking, in addition to increasing the risk of aneurysm rupture, is also a risk factor for 
aneurysm formation.29 Epidemiology and risk factors of aneurysmal SAH are discussed in 
paragraph 2.2.1. 
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2.1.2  Familial predisposition 
Familial intracranial aneurysms not associated with any of the known hereditable 
connective tissue disorders account for approximately 10 % (7–20 %) of aneurysmal SAH, 
and first-degree relatives of subjects with ruptured intracranial aneurysms have three- to 
sevenfold higher risk of aSAH than the general population.5,30-33 Familial intracranial 
aneurysms are reportedly more commonly multiple and rupture at a slightly smaller size 
and on average five years earlier than sporadic intracranial aneurysms.28 Aneurysms of the 
middle cerebral artery are over-represented and those of the anterior cerebral artery and 
posterior communicating artery are underrepresented among the familial intracranial 
aneurysms when compared to sporadic intracranial aneurysms.28,34,35 The rupture rate of 
unruptured cerebral aneurysms in the Familial Intracranial Aneurysm study cohort (1.2 % 
per year) was approximately 17 times higher than the rupture rate for subjects with an 
unruptured cerebral aneurysm in the International Study of Unruptured Aneurysm Study 
(0.069 % per year) with a matched distribution of aneurysm size and location.32,36 Aneurysm 
formation is a dynamic process and de novo aneurysms may form also after negative 
screening of the cerebral vasculature. In individuals with a family history of aSAH, a long-
term serial screening has been advocated since the yield of screening may be substantial 
even after more than 10 years of follow-up and two initial negative screens.37 
A number of genetic alterations have been associated with saccular aneurysms, most of 
which are moderators of cell cycle progression. Genome-wide genotyping of Finnish and 
Dutch cohorts and replication studies in a Japanese cohort identified common single 
nucleotide polymorphism on chromosomes 2q, 8q, and 9p that show significant association 
with intracranial aneurysms (OR 1.24–1.36).33 In a Finnish cohort, genome-wide linkage 
analysis showed linkage to 19q13 and Xp22, both of which were replicated in Japan.38-40 
Many of the identified genes affect the proliferation and senescence of cell populations that 
are primarily responsible for vascular formation and repair.  
2.1.3  Saccular intracranial aneurysms 
Intracranial aneurysms are classified, according to their morphology, into saccular and non-
saccular aneurysms. Saccular aneurysms account for more than 85 % of all intracranial 
aneurysms (Fig. 1).24,41 In general, saccular aneurysms develop when the cerebral artery 
wall becomes too weak to resist the hemodynamic pressure in the vessel, preferentially at 
the outer curvatures, bifurcations, or branching points of the brain vessels where 
hemodynamic stresses are maximal. Saccular aneurysms are extremely rare in pediatric 
population and are therefore almost exclusively acquired, not congenital lesions and 
develop with increasing age.42,43 Almost 90 % of saccular aneurysms occur on the anterior 
(i.e. carotid) circulation, most of them being situated on the circle of Willis.5,24 Although 
extensively studied, the definitive etiology of these focal outpouchings of the vessel wall 
remains largely unknown.  
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Figure 1. A schematic presentation (a) and a three-dimensional digital subtraction angiograph 
(DSA) reformation (b) of a typical saccular basilar tip aneurysm. 
 
Theoretically, all factors either deteriorating the tensile strength of the vessel wall or 
increasing the hemodynamic shear stress may predispose to aneurysm formation.  In 
animal models, cerebral aneurysms have been induced by a combination of hypertension 
and disruption of collagen synthesis.44,45 Association between apoptosis of medial smooth 
muscle cells and formation of saccular cerebral aneurysms was demonstrated in an animal 
model with induced cerebral aneurysms.46 In addition, degenerative changes in the internal 
elastic lamina related to early aneurysmal changes in another animal model, suggesting 
that aneurysmal alterations progress from the luminal towards the abluminal side of 
arterial wall if synthesis on the abluminal side is imbalanced with the catabolism on the 
luminal side of the vessel wall.47 Inflammation of the cerebral artery wall may also decrease 
the tensile strength thus predisposing to aneurysm formation. In immunohistochemical 
studies, however, the degree of inflammatory cell infiltration has been shown to be higher 
in ruptured than unruptured cerebral aneurysms, and inflammation seems to be a reaction 
to the ongoing degenerative processes in the aneurysm wall rather than the cause of the 
aneurysm.48 Consequently, the pathobiology behind aneurysm formation may be different 
from that of aneurysm rupture (see paragraph 2.2.2).  
Saccular aneurysms vary in size from very small (1–2 mm in diameter) to very large 
(several sentimeters in diameter). Intracranial aneurysms are classically categorized by their 
largest diameter into small (less than 10 mm), large (10 mm to 25 mm), and giant (over 
25 mm) aneurysms, although other categorizations are also frequently used (e.g. small 
<7 mm; medium 7–12 mm; large 13–24; giant ≥25 mm). Some saccular aneurysms remain 
stable over time, whereas some saccular aneurysms grow, sometimes regardless of any 
treatment attempts. Approximately 20–33 % of cerebral aneurysm patients have multiple 
aneurysms, about a third of these patients have three or more aneurysms, and less than 1 % 
of the aneurysm patients have six or more aneurysms.49-51 
2.1.4  Fusiform aneurysms 
In contrast to saccular aneurysms, fusiform aneurysms often involve long, nonbranching 
vessel segments and the demarcation between the normal and diseased vessel is less 
distinct in fusiform than in saccular aneurysms (Fig. 2). Often the fusiform aneurysm 
a b
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consists of most, if not all, of the parent artery circumference. Fusiform aneurysms can be 
either atherosclerotic or nonatherosclerotic, of which atherosclerotic fusiform aneurysms 
are substantially more common. Although a strong association between fusiform arterial 
dilatation and atherosclerosis has been reported, surgical and pathological studies of 
symptomatic fusiform aneurysms have shown contradictory results and atherosclerosis 
seems to be only one of the mechanisms in the pathogenesis of these lesions.52-55 Non-
atherosclerotic fusiform aneurysms are seen in younger patients and are often associated 
with an inherited vasculopathy or immune deficiency.56 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A schematic presentation (a) and a three-dimensional DSA reformation (b) of a 
fusiform internal carotid artery aneurysm. 
 
The term “dolichoectasia” (dilative arteriopathy) is used to refer to fusiform elongation of 
vessels without focal fusiform or saccular dilatations, alluding to their elongated and 
distended shape (derived from the Greek words dolichos, long or elongated, and éktasi, 
extension). It has been estimated that approximately one patient in eight who has 
intracranial vascular imaging has some increase in the length and diameter of intracranial 
arteries, most of which may be considered as physiological elongation and widening of the 
arteries, forming a certain overlap in the terminology between fusiform aneurysms, 
dolichoectasia, and normal elongation of the intracranial arteries.57,58 
If symptomatic at all, fusiform aneurysms may present with ischemic or compression 
symptoms. Since dilatative arteriopathy preferentially involves the intracranial vertebral 
and basilar arteries, the tortuous elongated arteries may generate pressure and distortion of 
brain structures especially in the medulla and pons as well as irritative symptoms caused 
by the stretching of cranial nerves (i.e. trigeminal pain, tinnitus, etc.)58 Dilatative 
arteriopathy may also cause ischemic strokes by distorting the orifices of arterial branches 
leading to decreased blood flow especially in penetrating branches of the large arteries, 
causing, for example, basilar artery branch territory infarcts in the pons.59 Rupture of 
fusiform aneurysms is unusual and most of these aneurysms have a benign prognosis.53,60 
a b
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2.1.5  Blister-like aneurysms 
Blister-like or blood blister-like aneurysms are small, thin-walled, and broad-based bulges 
frequently located at the non-branching, proximal part of the basal arteries of the anterior 
circulation (Fig. 3). Medial and anterior curvature of the terminal ICA segment not related 
to the choroideal or posterior communicating artery branches is the usual location for 
blister-like aneurysms, although other locations (e.g. basilar and anterior communicating 
arteries) are also possible. In pathological studies, focal arterial wall defects covered almost 
exclusively with fibrous tissue are demonstrated and blister-like aneurysms may originate 
from a focal dissection of the vessel wall.61,62 Blister-like aneurysms are rare, accounting for 
about 1 % of all intracranial aneurysms. In addition, it often remains unclear whether all 
radiological bulges of ICA are true blister-like aneurysms, especially in non-ruptured cases. 
Blister-like aneurysms are, however, known to be associated with much higher bleeding 
rates than saccular cerebral aneurysms and their fragile structure may also predispose to 
intraoperative rupture of the aneurysm.62-65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. A schematic presentation (a) and a three-dimensional DSA reformation (b) of a 
blister-like aneurysm of the internal carotid artery. 
2.1.6  Dissecting aneurysms and pseudoaneurysms (i.e. false aneurysms) 
Both dissecting aneurysms and pseudoaneurysms are characterized by a focal disruption of 
the vessel wall and are histologically not considered true aneurysms (Fig. 4). While 
dissecting aneurysms are contained by a thinned, often discontinuous adventitia, 
pseudoaneurysms are contained only by surrounding paravascular hematoma.66 Dissecting 
aneurysms and pseudoaneurysms may however be difficult to differentiate and they often 
result from a specific inciting event (e.g. infection, neoplastic process, vasculitis, rupture of 
true cerebral aneurysm or arteriovenous malformation, or [iatrogenic] trauma).67-69 
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Figure 4. A schematic presentation (a) and a three-dimensional DSA reformation (b) of a 
dissecting basilar artery sidewall aneurysm. 
 
The primary mechanism by which cerebral dissecting aneurysms are created is by the 
disruption of internal elastic lamina. The majority of these aneurysms have one entrance 
into the pseudolumen while some dissecting aneurysms have a clinically more stable 
configuration with both an entrance and exit.68 Intracranial artery dissection may also result 
in luminal stenosis, thromboembolism, and cerebral ischemia. Prognosis depends on 
clinical presentation, and presentation with SAH has a worse prognosis than presentation 
with cerebral ischemia.69 While both pseudoaneurysms and dissecting aneurysms are rare, 
the fragile structure of these lesions makes them susceptible to repeated hemorrhage and 
especially in pseudoaneurysms presenting with SAH, the rate of mortality can be high (14–
63 %).67-70 In a series of 12 rare peripheral posterior inferior cerebellar artery aneurysms, 
most were secondary to arterial dissection.71 The aneurysms were unstable with a high risk 
of rebleeding and a high mortality if not treated without delay, and endovascular treatment 
was effective in preventing rehemorrhage. 
2.1.7  Traumatic aneurysms 
Traumatic cerebral aneurysms are complications of closed and penetrating head injuries or 
may result also from surgical or endovascular procedures. They constitute less than 1 % of 
all intracranial aneurysms. Traumatic aneurysms may be caused either by direct injury of 
the arterial wall or by acceleration/induced shear, and it may be unclear whether they 
should be classified as (dissecting) aneurysms contained by surrounding hematoma and 
thinned tunica adventitia or pseudoaneurysms. Pathological findings, however frequently 
seem to reveal disruption of the three vascular layers fulfilling the definition of a 
pseudoaneurysm.66 
More than 50 % of traumatic cerebral aneurysms are reportedly associated with a skull 
fracture.72 Traumatic aneurysms typically arise near the skull base from the petrous or 
cavernous segments of ICA, from dural vessels, and especially in pediatric population also 
from pericallosal artery and its branches. In children, traumatic aneurysms observed after a 
severe head trauma are slightly overrepresented accounting for 14 % to 39 % of all 
aneurysms, partially due to the rareness of saccular aneurysms in this population.5,66 
a b
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2.1.8  Infectious aneurysms 
Infectious aneurysms are rare, accounting for 0.7 % to 6 % of all cerebral aneurysms, and 
can be caused by a myriad of pathogens.73,74 While often called mycotic aneurysms, the vast 
majority of infectious aneurysms result from bacterial infections. Bacterial aneurysms are 
typically found in patients with endocarditis and usually result from embolization of 
fragments of vegetations from an infected cardiac valve, and bacterial endocarditis carries 
an estimated risk of 3–10 % of aneurysm formation. Less commonly, infectious aneurysms 
result from direct extension of intracranial bacterial infections (i.e. meningitis, orbital 
cellulitis), often in immunocompromised patients.74,75 
Due to the presence of infection and destruction of the walls of the vessels, infectious 
aneurysms are typically thin-walled and friable, often with a wide or absent neck. 
Infectious aneurysms are associated with a higher risk of rupture and fatal hemorrhage 
when compared to other aneurysms. Even small infectious aneurysms can rupture and 
bleed fatally, and mortality rates of up to 80 % have been reported following infectious 
aneurysm rupture.76 In other, more recent series consisting of unruptured aneurysms, 
however, much lower mortality rates (12–32 %) have been reported.73-75,77 
2.1.9  Pediatric intracranial aneurysms 
Although a genetic component to aneurysm development and rupture have been 
demonstrated, very few saccular aneurysms are congenital (i.e. present at birth). In a 
systematic review of the literature, Garg et al. stated that pediatric aneurysms are 
uncommon as compared to aneurysms in adult patients, and there are many differences in 
the aneurysm etiology, location and morphological characteristics, and clinical presentation 
and outcome in pediatric and adult intracranial aneurysms.78 While pediatric aneurysms 
are heterogenous and can occur as a result of various etiologies, there is a high incidence of 
post-traumatic and infectious aneurysms in children.41  
Intracranial aneurysms cause the majority of spontaneous SAH in children and account 
for 10–15 % of hemorrhagic strokes in patients less than 20 years of age.79 Since pediatric 
aneurysms are frequently relatively large, develop a more complex shape, and have a 
predilection for the posterior circulation, seizures and cranial nerve involvement are seen 
more often as the presenting symptoms in children. In a series of 74 pediatric intracranial 
aneurysms in 62 children, the most common presenting feature was headache (82 %; 51 of 
62), followed by loss of consciousness (27 %; 17 of 62), limb weakness (23 %; 14 of 62) and 
seizures (21 %; 13 of 62).78 In a Finnish, population-based study of 114 pediatric patients 
with 130 aneurysms treated between 1937 and 2009, symptomatic de novo aneurysm 
formation was observed in six patients after a median of 25 years (range 11–37 years), and 
even a lifelong follow-up at five- to 10-year intervals was proposed for pediatric patients 
with ruptured intracranial aneurysms.80 
2.2  ANEURYSMAL SUBARACHNOID HEMORRHAGE 
Intracranial aneurysm rupture accounts for approximately 85 % of cases of nontraumatic 
SAH.24,41 Aneurysmal SAH is a devastating disease with overall 30-day case fatality rate of 
about 45 %. In addition, almost half of survivors are left disabled. Although SAH comprises 
only 3 % (1–7 %) of all strokes, SAH accounts for more than one-quarter of potential life 
years lost through stroke.41 Due to the poor clinical outcome and relatively young age of the 
affected patients, the loss of productive life years from aSAH is comparable to that of 
ischemic cerebral stroke, the most common stroke subtype.41,81,82 
2.2.1  Incidence and risk factors of aSAH 
The incidence of aneurysmal SAH is in Finland among the highest in the world. Whereas 
the age-adjusted incidence of aneurysmal SAH is approximately 11 per 100 000 per year in 
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most Western populations, it is about twice as much in Finland and in Japan.20-22 In a 
multinational epidemiological study, the age-adjusted annual SAH attack rates varied 10-
fold among the 11 populations studied, from 2.0 per 100 000 per year in China-Beijing to 
22.5 per 100 000 per year in Finland.20  
2.2.1.1  Patient-dependent risk factors of aSAH 
Statistically significant modifiable risk factors of aneurysmal SAH in longitudinal and case-
control studies were current smoking (RR 2.2), hypertension (RR 2.5), and excessive alcohol 
intake (RR 2.1).81,83 In addition, cocaine use has also been identified as a modifiable risk 
factor of aneurysmal SAH.2 Female gender and younger age at the beginning of the follow-
up may increase the risk of aneurysmal SAH, but the reported confidence intervals are 
relatively wide and the risk of rupture of a cerebral aneurysm seems to depend more on the 
characteristics of the aneurysm than on those of the patient.26,29,81,83,84 
Aneurysmal SAH is a strong risk factor for subsequent rerupture of the aneurysm. If a 
ruptured cerebral aneurysm is left unsecured, the risk of rerupture is estimated to be ca. 
20 % in the first two weeks after subarachnoid hemorrhage.85,86 Furthermore, prior history 
of aneurysmal SAH is a strong risk factor for aneurysm rupture also for unruptured 
cerebral aneurysms. In the International Study of Unruptured Intracranial Aneurysms 
(ISUIA), patients with unruptured intracranial aneurysms and prior subarachnoid 
hemorrhage had approximately 11 times higher rupture rates than patients with 
unruptured intracranial aneurysms and no prior history of SAH.87 
2.2.1.2  Aneurysm related risk factors of aSAH 
Aneurysm size (especially in patients who have not had previous SAH) and location have a 
significant role in determining the risk of future rupture of a cerebral aneurysm.3,88 In the 
ISUIA study, subjects with unruptured intracranial aneurysms of less than 7 mm in 
diameter and without a previous history of SAH, the rupture rate was very low (ca. 0.1 % 
annually). In giant aneurysms with a diameter of ≥25 mm the 5-year cumulative rupture 
rates were, on the other hand, as high as 50 % if the aneurysm was located in the posterior 
circulation or in the posterior communicating artery (PComA) (Table 1).3,36 The ISUIA study 
has, however, been criticised for multiple methodological inadequacies biased in favour of 
a benign natural history of small aneurysms.89,90 In addition, saccular aneurysms do not 
enlarge at a constant rate. The growth of saccular aneurysms is highly variable and 
unpredictable and although large aneurysm size is a known risk factor for aneurysm 
rupture and ruptured aneurysms are usually larger than unruptured aneurysms, the risk of 
rupture is not insignificant in small aneurysms and should not be predicted on aneurysm 
size alone.91,92 In a recent prospective Finnish cohort study of 118 patients with unruptured 
intracranial aneurysms diagnosed between 1956 and 1978 and followed up until death or 
SAH, the lifelong risk of aneurysm rupture was 29 % (34 of 118 patients).93 In small (<7 mm) 
unruptured aneurysms, the lifelong risk of aneurysm rupture was 25 % (24 of 96 patients). 
Aneurysm location also predicted aneurysm rupture in the ISUIA study: the relative risk 
of rupture was 2.3 if the aneurysm was in the tip of basilar artery, 2.1 if the aneurysm was 
located in the PComA, and 0.15 in the cavernous carotid artery, with internal carotid artery 
as the reference group. Although anterior communicating artery (AComA) aneurysms form 
30 % to 35 % of ruptured aneurysm series,  only 10 % to 15 % of more than 5500 patients 
had AComA aneurysms in the ISUIA study, implying that AComA aneurysms are prone to 
rupture early and do not tend to stabilize for a long time (i.e. be included in longitudinal 
studies involving unruptured cerebral aneurysms).36 Analogous results were shown in 
another cohort study with a very long follow-up data (median 21.0 years), in which 
AComA aneurysms showed a significant association with the risk of rupture while 
aneurysm location in the PComA and internal carotid bifurcation did not reach statistical 
significance.84 
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Table 1. 5-year cumulative rupture rates for patients without a history of subarachnoid 
hemorrhage (Wiebers et al. 2003). 
 
Aneurysm 
location 
Aneurysm size 
<7mm 7–12mm 13–24mm ≥25mm 
Cavernous 
carotid artery 
0 0 3.0 % 6.4 % 
ICA, AComA, 
ACA, MCA 
0 2.6 % 14.5 % 40 % 
Post., PComA 2.5 % 14.5 % 18.4 % 50 % 
 
In addition to aneurysm size and location, numerous aneurysm related risk factors (i.e. 
aneurysm shape, various size and shape ratios, flow angles, and contact between the 
aneurysm wall and surrounding anatomic structures) have also been identified.94-98 Studies 
on these morphological and geometric characteristics have, however, somewhat conflicting 
results, possibly due to variation in imaging techniques and other methodological 
differences.99 There is marked variation in the definition of aneurysm shape parameters, 
and there is a lack of consistency even in the definition of aneurysm size, which is the most 
ubiquitous parameter used in rupture risk assessment.95 Aneurysms with a daughter sac, 
however, were associated with a higher rate of rupture than aneurysms with a smooth wall 
also in a large prospective cohort of 5720 patients.88 
2.2.2  Aneurysm rupture as a biochemical process 
Considering the thinning and histopathological changes observed in the aneurysm wall 
and the increase in the hemodynamic load resulting from uneven wall shear stress and 
pressure distribution in the aneurysm sac, it may be more difficult to rationalize why an 
aneurysm does not inevitably rupture, rather than why it occasionally does. Nevertheless, 
the rupture of an aneurysm is a complex biochemical process, which is not yet fully 
understood. Cerebral aneurysms induced in animal models (e.g. by ligation of the common 
carotid artery combined with experimental hypertension and β-aminopropionitrile feeding) 
rarely rupture, suggesting that the pathobiology leading to formation of an intracranial 
aneurysm is not entirely identical to that leading to the rupture of an existing 
aneurysm.44,45,48 
Rupture-prone aneurysm wall is thought to develop when the equilibrium between 
vascular proliferation and degradation becomes disturbed. Loss of mural cells (e.g. due to 
excessive oxidative stress) along with the loss of functioning endothelium (e.g. due to 
aberrant flow conditions in the aneurysm lumen) have been presented as the key events 
which lead to intrinsic activation of cell death in the aneurysm wall and shift the balance 
towards aneurysm wall degeneration.100 Since mural cells seem to be essential for 
maintaining aneurysm wall homeostasis, loss of mural cells leads to aneurysm 
recanalization and increased inflammatory responces resulting in aneurysm wall 
degeneration, aneurysm growth, and eventual aneurysm rupture.101  Whether an 
intracranial aneurysm will eventually rupture or not seems to depend on both the 
hemodynamic shear stress and the biochemical responses leading to remodeling and 
restructuring of the aneurysm wall.48 
2.2.3  Clinical presentation, diagnostic studies, and imaging of aSAH 
The clinical presentation of aneurysmal SAH is often quite distinctive with a severe 
headache of sudden onset, which may be associated with additional signs and symptoms 
including nausea and/or vomiting, stiff neck, loss of consciousness, and focal neurological 
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deficits including cranial nerve palsies. An estimated 10 percent of the patients die before 
reaching medical attention, and many others present in coma or with severe neurologic 
compromise.25 However, because the type of headache from SAH is variable and nearly half 
of all patients with SAH have normal results on neurological examination as well as normal 
vital signs at initial presentation, misdiagnosis or delayed diagnosis of aSAH is relatively 
common with documented misdiagnosis rates of approximately 12 %.24,102-104 Misdiagnosis 
is reportedly associated with a nearly four-fold higher likelihood of death or disability at 
one year in patients with minimal or no neurological deficit at the initial visit.102 Since the 
most common diagnostic error is failure to obtain a nonenhanced cranial CT scan, a low 
threshold for CT scanning of patients with mild symptoms is advocated.4,102 
Clinical grading scales such as the Hunt and Hess scale (Table 2) are often used to 
objectively describe the neurologic condition on admission and are also considered 
relatively good predictors of clinical outcome.25,105 
 
Table 2. Hunt & Hess Grading Scale for subarachnoid hemorrhage (Hunt, Hess 1968). 
 
Grade Clinical presentation 
I Asymptomatic or mild headache 
II Moderate to severe headache; nuchal rigidity, and no neurologic deficit other than cranial-nerve 
palsy 
III Drowsiness, confusion, or mild focal deficit 
IV Stupor, moderate-to-severe hemiparesis, and possibly, early decerebrate rigidity and vegetatite 
disturbances 
V Coma, decerebrate rigidity, and moribund appearance 
 
Non-enhanced CT of the head is the initial diagnostic test of choice if SAH is clinically 
suspected. Lumbar puncture is traditionally recommended if the initial computed 
tomogram yields negative results, with bloody cerebrospinal fluid that fails to clear with 
continued egress or the presence of xanthocromia (yellowish discoloration of the CSF 
representing bilirubin from the breakdown of hemoglobin) raising a suspicion of SAH. In a 
large prospective multicenter study, modern computed tomography, when carried out 
within six hours of headache onset and interpreted by a qualified radiologist, was 
extremely sensitive and specific (sensitivity 100 % [CI 97.0 % to 100.0 %]; specificity 100 % 
[99.5 % to 100 %]; negative predictive value 100 % [99.5 % to 100 %]; and positive predictive 
value 100 % [96.9 % to 100 %]) in identifying subarachnoid hemorrhage.104  
In another study of 134 patients admitted with acute SAH and imaged with a 16-slice CT, 
the sensitivity of CT was 97.8 % (95 % CI 93.1–99.4 %) and none of the patients with 
negative CT had a lesion requiring intervention (Gee et al. 2012). In this setting, CT can be 
considered a “rule out” test for SAH and the need for lumbar puncture is questionable. If 
the CT was performed after six hours from the time of headache onset, however, the 
sensitivity dropped to 85.7 % (CI 78.3 % to 90.9 %), and when performed within six days 
after the onset of the symptoms, MRI (combination of fluid attenuated inversion recovery 
[FLAIR] and susceptibility weighted imaging [SWI]) yielded a distinctly higher detection 
rate for SAH than CT.104,106 
If SAH is detected in non-enhanced CT, CT angiography (CTA) is performed to detect 
possible underlying vascular pathology. CTA is a highly sensitive and specific non-invasive 
imaging method for diagnosis and evaluation of intracranial aneurysms, and CTA has been 
proposed as an alternative to DSA as a first-line imaging technique in patients with SAH.107 
However, in a prospective study of 200 SAH patients, the sensitivity of CTA, when 
compared to that of DSA, was 95.2 % in detecting cerebral aneurysms.108 The specificity of 
CTA was 97.2 %, positive predictive value 98.1 %, and negative predictive value 93.2 %. 
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Due to the suboptimal sensitivity and negative predictive values of CTA, continued use of 
DSA was recommended in patients with a negative CTA after acute SAH except for 
patients with classic perimesencephalic blood distribution.  
2.2.4  Complications of aSAH 
2.2.4.1  Vasospasm and delayed cerebral ischemia 
Delayed cerebral ischemia (DCI), defined either on the basis of cerebral infarction and 
functional disability or as a new onset of clinical deterioration not explained by other 
causes, is considered the most significant cause of morbidity and mortality in patients who 
survive the acute phase of SAH. DCI is used to complement older clinicoradiographic 
terminology (angiographic vasospasm and symptomatic vasospasm) as the pathogenesis of 
DCI in not fully attributable to large-vessel vasospasm. Angiographic vasospasm occurs in 
up to 70 % of SAH patients, but the relationship between angiographic spasm and clinical 
symptoms can be inconsistent.109,110 Other factors important in the pathophysiology and 
prognosis of DCI include disturbed cerebral autoregulation, global ischemia, disruption of 
the blood-brain barrier, microthrombosis, and activation of apoptotic and inflammatory 
pathways.111-113 
Cerebral vasospasm or rather delayed cerebral ischemia usually develops approximately 
one week after the hemorrhage and the condition worsens the prognosis of the hemorrhage 
significantly with poor outcomes occurring in up to 30 % of the affected patients despite 
aggressive therapy.114,115 In a Japanese study of 370 patients with ruptured aneurysms, the 
most important risk factors for cerebral vasospasm were SAH grade III-IV, left ventricular 
hypertrophy, cigarette smoking, and hypertension.116 Both DSA and CTA imaging are 
applicable in the evaluation of large-vessel vasospasm, but the hemodynamic alterations in 
cerebral perfusion leading to parenchymal ischemia can be assessed only by CT or MR 
imaging. Specifically CT perfusion (CTP) allows for rapid and noninvasive assessment of 
cerebral perfusion and is useful in the detection of DCI. In a systematic review, patients 
with aneurysmal SAH with perfusion deficits in CTP were approximately 23-fold more 
likely to experience DCI compared with SAH patients with normal CTP results.115 
Different combinations of hemodilution, hypervolemia, and hypertension have been 
used to increase cerebral blood flow in delayed cerebral ischemia. When all three 
components are used, the treatment combination is called triple-H therapy.117 In a 
systematic review on the effects of triple-H therapy, induced hypertension seemed to be the 
most promising in increasing cerebral blood flow (CBF). No good evidence was, however, 
found that CBF improves due to the intervention.118,119 Avoidance of hypotension, 
hyponatremia, hypovolemia, hyperglycemia, and hyperthermia has been recommended to 
prevent DCI in SAH patients.120 Intra-arterial papaverine, nimodipine, and balloon 
angioplasty have also been utilized in the treatment of vasospasm, often when triple-H 
therapy is ineffective or cannot be used due to risk of hemodynamic complications (e.g. 
heart failure or pulmonary edema).121 Both intra-arterial vasodilation administration and 
PTA have been shown to successfully reduce vasospasm and neurological deficits, 
although complications with both therapies (i.e. vessel rupture during PTA and intracranial 
hypertension and possible neurotoxicity associated with intra-arterial medical therapy) 
have also been reported.113,122-125 
2.2.4.2  Hydrocephalus and other complications of aSAH 
The range of the reported risk of hydrocephalus after aneurysmal SAH is wide, varying 
from 6 % to 67 % depending i.a. on the definition of hydcephalus, inclusion criteria, and 
timing of neuro-imaging studies.1,126,127 In a large study of 3521 SAH patients, the most 
important variables associated with clinically symptomatic hydrocephalus were the 
findings of hydrocephalus and intraventricular hemorrhage on admission CT, impaired 
level of consciousness at admission, preexisting and postoperative hypertension, increasing 
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age, and posterior circulation aneurysm site.128 Other factors, such as hyponatremia and the 
use of antifibrinolytic drugs preoperatively contributed also to the development of acute 
hydrocephalus and the development of hydrocephalus after SAH was concluded to be 
multifactorial. While external ventricular drainage is required in approximately half of the 
patients with acute hydrocephalus, permanent CSF diversion is required in only 10–20 % of 
the cases. Risk factors for shunt-dependent hydrocephalus were the presence of intra-
ventricular hemorrhage, lower mean score of Glasgow Coma Scale, and complications with 
post-operative intra-cerebral hemorrhage.127 
Benign cardiac abnormalities (e.g. ST segment depression, prolonged QT segments, and 
tall peaked T-waves) are common in the first 48 hours after SAH, and cardiac enzymes are 
often mildly elevated.6 Only in rare cases the neurogenic cardiopulmonary abnormalities 
are severe (e.g. fall in cardiac output; development of pulmonary edema).129 Fever, anemia, 
hyperglycemia, hyponatremia, hypertension, and pneumonia have also been reported as a 
complication of SAH, and hyponatremia may also be an independent risk factor for poor 
outcome.4 Although a large number of seizure-like episodes have been associated with 
aneurysmal rupture, the risk and implications of seizures associated with SAH are not well 
defined and it is unclear whether all these episodes are epileptic in origin. Nonrandomized 
studies of craniotomy patients have indicated a benefit of prophylactic anticonvulsants, but 
the number of patients has been relatively small in these studies and the routine use of 
prophylactic anticonvulsants during the perioperative period is still ambiguous.4,130-132 
2.2.5  Non-aneurysmal SAH 
Approximately 15 % of patients with non-traumatic SAH have normal cerebral 
angiograms.133 The definitive cause of angiogram-negative SAH has not been established 
although various pathogenetic causes (i.e. abnormalities in the venous structures, capillary 
or perforating artery ruptures, intramural hematomas, and low-flow vascular 
malformations) have been suggested.134-137 The clinical outcome in patients with 
nonaneurysmal SAH is substantially better than in patients with aneurysmal SAH, 
although two distinct subsets of patients with angiogram-negative SAH should be 
recognized, namely perimesencephalic and non-perimesencephalic non-aneurysmal 
SAH.133 Especially patients with a perimesencephalic pattern of hemorrhage have an 
excellent prognosis with a clinically good outcome in 89–100 %.138-141 In addition, the long-
term mortality in patients with perimesencephalic SAH does not differ from that observed 
in the general population.138 
2.3  CLINICAL OUTCOME AFTER aSAH 
Aneurysmal SAH is often a devastating event. Approximately 10 % of patients with aSAH 
die prior to reaching medical attention, 25 % die within 24 hours of aSAH onset, and about 
45 % die within 30 days. Only a third of the patients will have a good outcome after 
treatment.1-6 There are, however relatively wide variations in case fatality rates reported 
between different studies and slightly declining mortality rates during the past several 
decades have also been suggested, presumably explained by the improved management of 
patients with aSAH.20,142,143 
The clinical outcome after aSAH is often assessed with Glasgow Outcome Scale (GOS), 
which allows standardized descriptions of the objective degree of recovery (Table 3).144  
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Table 3. Glasgow Outcome Scale (GOS) (Jennett, Bond 1975). 
 
Grade Clinical outcome 
1 Death 
2 Persistent vegetative state 
3 Severe disability (conscious, but totally dependent on others) 
4 Moderate disability (neurological deficit or intellectual impairment, but independent life) 
5 Good recovery (independent life, no or minimal neurological deficit) 
 
In addition, modified Rankin Scale (mRS) is often used to assess the degree of disability or 
dependence in the daily activities after aSAH (Table 4).145 An additional grade (6; death) is 
often added to mRS classification. 
 
Table 4. Modified Rankin Scale (mRS) (Farrell et al. 1991). 
 
Grade Clinical outcome 
0 No symptoms at all 
1 No significant disability and able to carry out all duties 
2 Slight disability. Unable to carry out some previous activities but able to look after own affairs 
without assistance 
3 Moderate disability. Requiring some help but able to walk without assistance 
4 Moderately severe disability. Unable to walk without assistance and unable to attend to own 
bodily needs without assistance 
5 Severe disability. Bedridden, incontinent and requiring constant nursing care and attention 
 
Factors influencing on outcome after aSAH can be divided into patient factors, aneurysm 
factors, and institution factors.4 Patient factors include the severity of the initial 
haemorrhage, age and sex of the patient, and medical comorbidities (e.g. hypertension, 
atrial fibrillation, coronary arery disease, congestive heart failure). Aneurysm factors 
include the size, location, and morphology of the ruptured aneurysm, and institutional 
factors include for instance the availability of surgical and endovascular services and the 
volume of aSAH patients treated.146-149 
The severity and extent of the initial hemorrhage is the main determinant of clinical 
outcome after aSAH.143,150 SAH is thought to reduce cerebral blood flow and decrease 
cerebral perfusion i.a. by inducing vasoconstriction and reducing cerebral autoregulation, 
activating microvascular collagenases and platelet aggregation, and by decreasing the 
availability of nitric oxide.4,150-152 Recurrent hemorrhage, with a case fatality rate of 
approximately 70 %, is the most important treatable cause of poor outcome.25,153 The risk of 
rebleeding is between 20 % and 30 % in the first month after aSAH and then stabilizes to a 
rate of approximately 3 % per year.4,25 It has also been suggested that the risk of “ultraearly 
rebleeding” (i.e. within 24 hours of initial SAH) may be up to 15 %.154-156 Of the institutional 
factors it has been observed that concentrating the care of aSAH patients to high-volume 
SAH treatment centers seems to improve the overall survival after aSAH.146,148,149 
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2.4  TREATMENT OF INTRACRANIAL ANEURYSMS 
As approximately 20 to 30 percent of the ruptured aneurysms hemorrhage again within the 
first month after aSAH, the treatment of ruptured intracranial aneurysms is well 
grounded.4,25 The management of unruptured cerebral aneurysms is, however, still much 
more controversial because of incomplete and conflicting data about the natural history of 
these lesions and the risks associated with their treatment. Based on the results of the ISUIA 
study, medical management and observation may be the best treatment method for many 
patients with unruptured small aneurysms especially in the anterior circulation.36 On the 
other hand, the risk of small aneurysm rupture is not insignificant and the risk of aneurysm 
rupture should not be predicted on aneurysm size alone.93 There seems to be a twofold to 
threefold increase in the risk of aneurysm rupture in Finnish (and Japanese) populations 
when compared to other populations, which supports the treatment of smaller unruptured 
aneurysms in Finnish population.21,22 Many factors (i.e. the location, size, and morphology 
of the aneurysm as well as the method- and often age-specific risks of different treatment 
modalities) should be evaluated for each patient before initiating any treatment regimen for 
patients with unruptured cerebral aneurysms (see paragraph 2.2.1).  
The operative treatment of intracranial aneurysms falls into two main categories, namely 
microsurgical treatment and endovascular techniques.  
2.4.1  Microsurgical treatment 
The first surgical ligation of an intracranial aneurysm was performed by Walter E. Dandy 
in 1937 and Yaşargil introduced the systemic use of noninvasive and atraumatic 
microsurgical techniques in the 1960s.157-160 When an aneurysm is microsurgically clipped, 
the base of the aneurysm is closed by apposing the aneurysm walls which occludes the 
aneurysm completely and leaves the parent artery patent and unobstructed. The goal of 
microsurgical aneurysm treatment is to achieve complete and permanent exclusion of the 
aneurysm from the circulation while preserving the parent artery and possible perforating 
or branching vessels arising from the parent vessel. The complete closure of the aneurysm 
sac seems to be of pivotal importance in the prevention of rebleedings and regrowth of the 
aneurysm.29,158,161  
Microsurgical operations are performed with the aid of a high magnification microscope, 
preferably with integrated near-infrared indocyanide green videoangiography (ICG-VA) 
which provides real-time information about the patency of branching vessels and about the 
aneurysm sac.162,163 The refinement of skull base approaches provides an effective, targeted 
surgical field. Pterional, lateral supraorbital, orbitozygomatic, or the interhemispheric 
approach is used to access aneurysms in the anterior circulation while pterional, lateral 
suboccipital or subtemporal approach may be used to access posterior circulation 
aneurysms. The dissection of the aneurysm as well as adjacent vessel branches may be 
facilitated by the use of temporary clips. The duration of each temporary occlusion should 
be kept as short as possible (typically less than five minutes) to prevent parenchymal 
ischemia. Adequate dissection around the aneurysm base, properly sized and shaped 
occluding clip, and careful positioning of both of the blades of the clip are required to 
preserve the patency of the main vessel trunks and possible perforating branches. If the first 
clip slides or some of the aneurysm neck remains exposed, another clip may be introduced 
proximal to the previous one for final closure.159,164-166 In addition to direct microsurgical 
clipping, aneurysm wrapping, trapping with or without bypass surgery, parent vessel clip 
reconstruction, endoaneurysmectomy, retrograde suction decompression, and other 
surgical methods may also be utilized especially in the surgical treatment of complex 
intracranial aneurysms.  
The range of mortality and morbidity ranges reported in the surgical series is wide, 
periprocedural mortality varying from 0 % to 7 % and permanent morbidity varying from 
4 % to 15.3 %.3,167-170 In a meta-analysis of 2460 patients in 61 studies published between 1966 
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and 1996, procedure-related morbidity was 10.9 % and mortality 2.6 %.170 In a recent study 
on clip ligation of unruptured intracranial aneurysms, the risk of poor surgical outcome 
was shown to be increased in patients presenting with age older than 60 years, ischemic 
cerebrovascular disease, posterior circulation aneurysms, presence of preoperative 
disability, and an aneurysm size of >25 mm.171 Microsurgical therapy of giant and posterior 
circulation aneurysms is well documented55,172-175, but especially in giant aneurysms surgical 
therapy may be challenging due to poor visibility to the neck of the aneurysm, the presence 
of a multitude of small perforating vessels (e.g. lenticulostriate, thalamostriate, and basilar 
perforating vessels), and occasionally due to large branches (e.g. M2 segments of the MCA) 
arising from the aneurysm sac. 
The incidence of aneurysm remnant after microsurgical intervention varies from 1.8 % to 
3.6 % even in specialized centers while parent artery occlusion is detected on postoperative 
angiography in 1.6 % to 21 % of the cases.176,177 In a series of 808 surgically treated 
aneurysms, 12 % (97 of 808 aneurysms) of the clipped aneurysms were incompletely 
occluded, of which 61 % (59 of 97 aneurysms) were unexpected on postoperative 
angiograms.158 Major vessel or branch occlusions were detected in 44 patients (5 %), 32 of 
which were unexpected. In a recent report of 246 procedures (232 patients and 295 
aneurysms) performed with the aid of intraoperative ICG-VA, the clip position was 
modified intraoperatively as a consequence of ICG-VA in 9 % of the procedures (22 of 246), 
and in another 11 procedures (4.5 %) additional clips were applied due to observed residual 
aneurysm perfusion. Small (<2 mm) wide-necked aneurysm remnants were however 
missed in up to 10 % of patients and even a 6 mm residual aneurysm was missed by 
intraoperative ICG-VA in this study.176 Based on these results, postoperative DSA imaging 
after aneurysm surgery seems justifiable even when surgeons have extensive experience 
with aneurysm surgery and have the highest technical standards available. 
The relative proportion of aneurysms assigned into microsurgical and endovascular 
treatment varies considerably (from approximately 10 % up to 90 %) between centers and 
depends mainly on the experience of the attending neurosurgeons and interventional 
neuroradiologists. If either the microsurgical or the endovascular group is very small, some 
of the benefits of each treatment method are inevitably lost, and at least a few easier cases 
are also periodically required for each treatment category for practice and improving of the 
technique. Microsurgical clipping still represents the most efficient and durable treatment 
of for example unruptured MCA aneurysms, especially in the presence of a wide neck or if 
an arterial branch originates from the aneurysm neck.178-181 Surgery is the main option of 
treatment also for many small cerebral aneurysms which are often difficult to treat by 
endovascular coil embolization.182 In addition, the development of intracranial-intracranial 
bypasses is another important advancement that makes microsurgery a competitive option 
for the treatment of complex and recurrent cerebral aneurysms.183-185  
Microsurgical aneurysm therapy is not only ethically defendable in view of the clinical 
outcome, but is also in line with a strategy to maintain and develop surgical experience 
within neurovascular centers. Technological advances (e.g. the development of endoscopic 
techniques, electrophysiological monitoring of the patient, the introduction of micro 
vascular Doppler ultrasonography, and the implementation of ICG-VA) have promoted 
surgical therapy in the same way as novel techniques (e.g. improved coils and flow-
diverting stents) have revolutionized endovascular aneurysm therapy.  
2.4.2  Endovascular treatment 
The purpose of endovascular aneurysm therapy is to exclude the aneurysm from the 
circulation either by endosaccular occlusion or by flow diversion and parent vessel 
reconstruction. The endovascular approach to aneurysm occlusion has the theoretical 
advantage of avoiding craniotomy and brain manipulation, but is nevertheless associated 
with numerous challenges (i.e. the risk of periprocedural aneurysm rupture, occurrence of 
arterial dissections and/or thromboembolic complications, reactions to contrast material, 
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and puncture site complications). Since the initial publication of the results of the 
International Subarachnoid Aneurysm Trial (ISAT) in 2005, endovascular treatment of 
intracranial aneurysms has been firmly established.153 In the ISAT study, 2143 patients with 
ruptured intracranial aneurysms admitted to 42 neurosurgical centers mainly in the UK 
and Europe, were randomly assigned either to neurosurgical clipping (N=1070) or 
endovascular coiling (N=1073). It was observed that in patients suitable for both treatments, 
endovascular coiling was more likely to result in independent survival at one year than 
neurosurgical clipping and that the survival benefit continued for at least seven years. The 
risk of rebleeding was low in both groups, but was more common after endovascular 
coiling than after neurosurgical clipping.153 In the long-term follow-up of the ISAT study 
published in 2009, it was observed that there was an increased risk of recurrent hemorrhage 
from coiled aneurysms compared with clipped aneurysms, but the risks were small in both 
groups.186 
The ISAT study has been criticised for biases regarding patient selection and center 
participation, as well as for differences in practitioner experience in the endovascular and 
microsurgical groups.187-189 Considering these study limitations, the results of the ISAT 
study should not be directly extrapolated to all patients with ruptured intracranial 
aneurysms, and even less to unruptured aneurysms. The safety and efficacy of 
microsurgical clip occlusion and endovascular coil occlusion for the treatment of acutely 
ruptured cerebral aneurysms was also compared in the Barrow Ruptured Aneurysm Trial 
(BRAT). Based on mRS scores at three years, the outcomes of all patients assigned to coil 
embolization showed a favourable 5.8 % absolute difference compared with outcomes of 
those assigned to clip occlusion, but patients in the surgical group had a significantly 
higher degree of aneurysm obliteration and a significantly lower rate of recurrence and 
retreatment.190 In the first published prospective randomized study comparing early 
endovascular and surgical treatment of ruptured cerebral aneurysms, the one-year clinical 
and neurophysiological outcomes in endovascular treatment were equal to the outcomes of 
acute surgical clipping of the ruptured aneurysm.191 Endovascular treatment of the 
ruptured aneurysm was significantly less-often associated with MRI-detectable brain injury 
than surgical clipping, but was associated with a slightly poorer total occlusion rate of the 
aneurysm and with the need for repeated angiographic controls with possible re-
embolization procedures (see paragraph 2.5). When long-term outcome of the brain was 
prospectively evaluated with MRI one year after endovascular or neurosurgical treatment 
for aSAH, parenchymal high-signal intensity lesions on T2- and intermediate-weighted MR 
images were more frequent after surgical treatment and lesion volumes also correlated with 
neuropsychologic test performance.192 
2.4.2.1  Coil embolization 
In endovascular coil embolization, a microcatheter is advanced into the aneurysm sac and 
the aneurysm is occluded with very soft detachable platinum coils of various sizes and 
shapes. Coil embolization was first introduced into clinical use in 1991 by Guglielmi et al. 
after the technology to produce microcatheters soft enough to navigate atraumatically into 
the aneurysm sac became available.193,194 Since then, numerous different coils with special 
attributes (e.g. coils with different 2D or 3D morphologies; bioactive coils with polyglycolic 
acid, polyglycolic/polylactic acid, or hydrogel coating) have been developed.195-198 While the 
safety profiles of bioactive coils seem comparable to those of bare platinum Guglielmi 
Detachable Coils (GDCs), superiority for either coil type is not established.199 The evidence 
of sustained benefit of bioactive coils over bare platinum coils remained equivocal also in a 
review of the multiple trials and clinical series published on bioactive coils.200  
The immediate angiographic result of aneurysm occlusion after coil embolization is often 
assessed with Raymond-Roy Occlusion Classification scale (Fig. 5). In this classification, 
residual neck (i.e. neck remnant) is defined as the persistence of any portion of the 
aneurysm of the original defect of the arterial wall as seen on any single projection but 
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without opacification of the aneurysm sac, whereas any opacification of the sac is classified 
as residual aneurysm and considered a failure of treatment.201,202 While Raymond-Roy 
classification is useful in the evaluation of immediate angiographic results of aneurysm 
occlusion, it was not designed to predict recurrence rates.203 
 
 
 
Figure 5. Classification of angiographic result after coil embolization by Roy et al. (Roy, Milot & 
Raymond 2001): class 1, complete occlusion; class 2, residual neck; class 3, residual aneurysm. 
 
The morbidity and mortality rates associated with coil embolization of cerebral aneurysms 
depend markedly on many factors including the size and morphology of the aneurysm, 
target vessel anatomy, co-morbidities of the patient, and rupture status of the aneurysm. 
Usually the rate of adverse effects reported with coil embolization is approximately 10 % 
(8–21 %), of which less than half result in permanent clinical sequelae (1.0–5.2 %). 
Procedure related mortality rate ranges from 0.5 % to 1.7 % in larger, unselected 
series.5,153,196,201,204-207 Of the major complications associated with coil embolization of 
intracranial aneurysms, thromboembolic complications are the most common. The 
estimated incidence of thromboembolism is in the range of 3–10 %, with permanent deficits 
in 3–5 %.206,208,209 Puncture site complications are rare, with an incidence of less than 1 %.204 
Periprocedural aneurysm rupture occurs in about 3 %, and is more frequent in small 
(≤3 mm) and ruptured aneurysms.210 Often the high risk of natural history of the aneurysm 
is associated with a high procedural risk (e.g. a giant basilar tip aneurysm would have a 
cumulative 5-year rupture risk of 50–60 % as well as a high periprocedural complication 
risk).36 
2.4.2.2  Balloon-assisted embolization 
The main factor limiting endovascular treatment of intracranial aneurysms is challenging 
morphology of the aneurysm sac. Endovascular treatment of wide-necked cerebral 
aneurysms is especially challenging since the coils used in the embolization may tend to 
protrude from the aneurysm sac into the parent artery. Moret et al. introduced in 1997 a 
novel technique to occlude wide necked cerebral aneurysms by temporarily inflating a non-
detachable balloon in front of the aneurysm neck during each coil placement, a technique 
which the authors called “remodelling technique”.211 In this study, 56 aneurysms which 
were considered to be untreatable with conventional coil embolization due to wide-necked 
or otherwise challenging profile were selected for treatment with balloon-assisted 
embolization, and the remodelling technique allowed the treatment of 52 of these 
aneurysms with a low technique-related morbidity (1 of 52; 0.5 %) and mortality (0 of 52). 
The remodelling technique thus seemed to extend the spectrum of endovascularily 
treatable aneurysms without increasing the risk incurred by the treatment.  
New, very compliant balloon-occlusion microcatheters have been subsequently 
developed, extending the usability of the remodelling technique to ever smaller vessels and 
more challenging arterial bifurcations, and the technique is now widely adopted.212-217 A 
double-balloon remodelling technique has also been developed to allow the endovascular 
embolization of exceedingly broad-based bifurcation aneurysms (e.g. basilar artery 
bifurcation aneurysms).218,219 
   
1 2 3
20 
 
 
2.4.2.3  Conventional intracranial stents and stent-assisted embolization 
Although coil protrusion into the parent artery may often be prevented with balloon-
assisted remodelling technique, additional support or remodelling of the aneurysm neck is 
occasionally required. This can be achieved by deploying a stent over the aneurysm neck 
before coiling. Intracranial stents have been extensively studied, but the published data on 
stent-assisted coil embolization consists mostly of results in patients with nonruptured 
aneurysms treated in an elective setting.8,9,220-230 The data on ruptured wide-necked 
aneurysms remains relatively scarce and the results of stent-assisted embolization in acute 
SAH are somewhat controversial.12,222,228,231-234  
There are several theoretical advantages in using stents in the management of 
intracranial aneurysms: in addition to reducing the risk of coil protrusion into the parent 
artery, an intracranial stent provides a physical matrix for possible endothelial growth 
across the aneurysm neck and disturbs the inflow jet to the aneurysm sac, thus promoting 
aneurysm thrombosis. In an interesting study with an aneurysm model, Canton et al. 
showed that the use of flexible intravascular stent effectively reduced the strength of the 
vortex forming in an aneurysm sac and results in a decrease in the magnitude of stresses 
acting on the aneurysm wall.235,236 Furthermore, the measured flow velocity and shear stress 
consistently decreased with the addition of each successive stent. Possibly due to this flow 
reduction and decrease in the shear stress in the aneurysm sac, deployment of an 
intracranial stent seems also beneficial with respect to reducing the recanalization rate of 
cerebral aneurysms.10,237 In wide-necked aneurysms located at arterial bifurcations, 
narrowing of the bifurcation angle and additional support to the aneurysm neck may also 
be provided by the ‘Y-stent’ technique, whereby dual stents are deployed sequentially into 
each arterial branch.238-240  
The Neuroform stent (Boston Scientific/Target Therapeutics, Fremont, CA, USA), a 
flexible, self-expanding, nitinol stent specifically designed for use in the cerebral 
vasculature, became available for aneurysm treatment in November 2002 and it was for 
many years the only available commercial stent for intracranial stenting. In recent years, 
however, many other stents have also been developed to address very specific challenges 
and to increase the number of aneurysms eligible for endovascular treatment. Although all 
of the conventional intracranial stents are laser-cut nitinol stents, the features of the stent 
vary depending on the profile and structure of the stent: it is generally accepted that stents 
with open cell design (i.e. adjacent cells formed by the strands of the stent are not 
interconnected) conform adequately also in tortuous vessels while stents with closed cell 
design (i.e. with adjacent cells interconnected) are usually re-sheathable and may have 
superior scaffolding across the aneurysm neck.  
2.4.2.4  Flow-diverting stents  
The clinical relevance of the flow diversion effect of intracranial stents was first discovered 
incidentally when aneurysm thrombosis was observed while performing staged stent-
assisted aneurysm embolization by deploying a conventional intracranial stent across the 
aneurysm neck several weeks before the intended coiling of the aneurysm.241,242 This flow-
diversion effect is intensified with flow-diverting stents, which are specifically designed for 
the endovascular reconstruction of a segmentally diseased artery by redirecting the blood 
flow away from the aneurysm neck. Flow-diverting stents have a dense mesh geometry and 
a very high metal-to-surface coverage which induces stronger turbulence and flow 
reduction than that induced by conventional intracranial stents, potentially inducing 
thrombosis in the aneurysm sac. While the metal surface coverage of conventional 
intracranial stent is usually around 10 %, the dense mesh of flow diverting stents provide a 
metal surface area coverage of ca. 35 % to 55 %, depending on the stent size and parent 
vessel diameter. Therefore, flow-diverting stents represent a paradigm shift in the 
treatment philosophy for endovascular therapy of aneurysms from endosaccular occlusion, 
with the goal of flow redirection and parent vessel reconstruction. 
21 
 
 
The efficacy of flow-diverting stents was first demonstrated in several animal 
studies.243,244 The results of the first larger clinical study (53 patients with 63 aneurysms 
treated with Pipeline Embolization Device [PED]) published by Lylyk et al. in 2009 were 
nothing short of revolutionary: complete occlusion of the stented aneurysm in 94 % of the 
patients within available follow-up with no major clinical adverse effects either 
periprocedurally or during the available follow-up period.14 Reports of hemorrhagic and 
thromboembolic events associated with flow-diverting stents were however soon 
published, limiting the use of flow-diverting stents mostly to the endovascular treatment of 
complex intracranial aneurysms.15-18 
The latest reports on flow-diverting devices have had variable and even somewhat 
conflicting results. Efficacy and favourable safety profile of flow-diverters has been shown 
in several well-designed studies245-247, but on the other hand, in a recent, relatively large 
study of 80 patients with 84 flow-diverting stents, only 49 patients (58 %) had no 
complications while procedure-related mortality was 5.9 % and permanent new deficit was 
encountered in eight patients (9.5 %).19 In smaller retrospective series flow-diverting stents 
have been successfully utilised also in the treatment of fusiform cerebral aneurysms248, 
ruptured blister-like aneurysms249, and treatment with a flow-diverting device has also been 
recommended as a primary treatment method for recurrent aneurysms.247  
In a recent study of 178 patients treated either with a single PED (N=126) or multiple 
overlapping devices (N=52), complications occurred more frequently with multiple (15 %) 
versus a single device (5 %; P=0.03), and the use of multiple devices predicted 
complications also in multivariate analysis.250 In this study, a significantly higher 
proportion of patients treated with a single device (97 %) achieved a favourable outcome 
compared with those treated with multiple devices (89 %, P=0.03). These findings suggest 
that treatment with a single flow-diverting device may be sufficient for treatment of most 
intracranial aneurysms and seems to provide similar occlusion rates with less complications 
and better overall outcomes than treatment with multiple overlapping stents.  
2.4.2.5  Embolization with liquid embolic agent 
A non-adhesive high-viscosity liquid embolic agent (Onyx; ev3 Neurovascular, Irvine, CA, 
USA) has also been used to treat cerebral aneurysms, with reportedly similar morbidity and 
mortality rates to those of other current endovascular techniques.251-254 Onyx is comprised of 
20 % ethylene vinyl alcohol (EVOH) copolymer dissolved in dimethyl sulfoxide (DMSO), 
and suspended micronized tantalum powder to provide contrast (i.e. visualization under 
fluoroscopy). When the material comes into contact with blood it precipitates and forms a 
soft polymer cast, which solidifies over a period of ca. 10 minutes. 
In addition to allowing theoretically nearly 100 % volumetric occlusion of the aneurysm 
sac (as opposed to the optimal occlusion rate of ca. 30 % with coil embolization), Onyx 
induces reportedly intense neoendothelialization reaction which may lead to complete 
aneurysm exclusion from the circulation.252,255,256 During Onyx injection, a remodeling 
balloon is typically inflated in the parent artery to protect it against leakage of the liquid 
embolic agent. The balloon must be intermittently deflated to allow cerebral reperfusion, 
and Onyx embolization conventionally involves repetitive cycles of balloon inflation and 
deflation.  
In a prospective observational multicenter study conducted in 20 European centers, 
Onyx treatment was noted to offer a feasible endovascular treatment alternative for selected 
patients with aneurysms that were unsuitable for coil treatment or in whom previous 
treatment had failed to occlude the aneurysm.253 In this study, aneurysm occlusion rates 
were reportedly superior to reported rates of coil occlusion for this subgroup of patients 
with either complete or subtotal occlusion in 65 of 71 aneurysms (92 %). Procedure- or 
device-related permanent neurologic morbidity was recorded in eight of 97 patients (8 %), 
procedure-related mortality rate was 2 % (2 of 97 patients), and delayed occlusion of the 
parent vessel occurred in nine patients.253 Although complete aneurysm occlusion with 
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Onyx and protective devices and/or balloon remodeling technique seems feasible, 
migration of the liquid embolic agent into the parent artery remains a difficult challenge 
and the advent of flow-diverting stents has considerably decreased the use of Onyx in the 
treatment of complex intracranial aneurysms.252 
2.4.2.6  Intrasaccular flow-disruption treatment 
The WEB (Woven EndoBridge Cerebral Aneurysm Embolization Device; Sequent Medical, 
Aliso Viejo, CA, USA) is an intrasaccular ellipsoid braided-wire embolization device 
designed to provide blood flow disruption at the level of the aneurysm ostium.257-259 The 
WEB demonstrated promising results in an experimental animal study259, but the clinical 
data on the device remains scarce. In the biggest clinical series to date of 19 patients with 20 
unruptured wide-necked bifurcation aneurysms treated by WEB placement, complete 
occlusion of the aneurysm was detected in two patients (11 %), near-complete occlusion in 
15 patients (79 %), and incomplete occlusion in two patients (11 %).257 Failure of the WEB 
placement occurred in one case (5 %) and a symptomatic neurological complication was 
encountered in two (11 %) cases. Further studies are needed to evaluate the indications, 
safety, and efficacy of this novel technique.  
2.4.2.7  Covered stents (stent-grafts) in the treatment of intracranial aneurysms  
Covered stents have also been used to treat intracranial (mainly distal ICA and VA) 
aneurysms with a high technical success, although the reported studies have mostly been 
based on single-center experiences.260-264 In a small study of eight patients, covered stents 
have also been used safely and effectively to occlude recurrent aneurysms.262 The main 
concern over using covered stents in the cerebral vasculature is the closure of side branches 
or perforating arteries originating from the covered arterial segment. Although the risk of 
side branch occlusion and subsequent stroke may be reduced by performing a balloon 
occlusion test prior to stent insertion, the risk of subsequent stroke is higher than with flow 
diverting devices.260 While relatively good flexibility and efficacy of the stent have been 
reported in selected patients, the use of covered stents may also be limited due to the 
relative stiffness of the device and covered stents are not considered as the first-line 
treatment of intracranial aneurysms. 
2.5  FOLLOW-UP AND RECURRENCE OF ENDOVASCULARLY TREATED 
ANEURYSMS 
Aneurysm recurrence is relatively common after coil embolization, and the risk of 
aneurysm reopening is about 20 % in larger studies.153,207,265-267 However, recurrence rates of 
up to 33.6 % have been reported, appearing at a mean time of 12.3 months after treatment 
(Table 5).202 The durability of endovascular coil occlusion is thought to depend largely on 
the initial packing density achieved in the aneurysm sac, but coil compaction and aneurysm 
recanalization may occur even in aneurysms that appear completely occluded after the 
initial treatment.198,268-271  
In the ISAT study, retreatment was 6.9 times more likely after endovascular therapy than 
after surgical clipping, the mean time to retreatment being 20.7 months.266 Of 2143 patients 
randomly assigned to clipping or coiling, rebleeds from the treated aneurysm was detected 
in 13 patients, 10 of which in the endovascular group and three in the surgical group.186 
Since microsurgically treated aneurysms are usually not angiographically followed, the 
exact incidence of aneurysm regrowth after surgical treatment is unknown but seems to be 
low and associated with incompletely treated aneurysms with residual necks, which 
emphasizes the importance of optimal clip placement in the microsurgical aneurysm 
therapy.158,272,273  
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 Retreatment of previously embolized aneurysms has on average a low complication rate 
and does not negate the advantage of the initial embolization.274 Long-term monitoring of 
patients treated by endosaccular coiling seems mandatory, but the recommendable length 
of angiographic follow-up is not yet established. Increasing angiographic stability has been 
demonstrated in embolized aneurysms up to three years from coil embolization, suggesting 
follow-up angiography until this time.275 In individuals with a family history of aSAH, the 
yield of long-term screening is however substantial even after more than 10 years of follow-
up and two initial negative screens.37, advocating longer angiographic follow-up in these 
cases.   
 
Table 5. Overview of recurrence and retreatment rates of embolized intracranial aneurysms in 
observational studies. 
 
Series # of patients # of aneurysms Recurrence 
rate 
Retreatment 
rate 
Campi A et al. 2007 1096 - - 17.4 % 
Ferns SP et al. 2009 - 8161 20.8 % 10.3 % 
Gonda D et al. 2014 944 - - 20.4 % 
Henkes H et al. 2008 2360 2759 - 12.3 % 
Raymond J et al. 2003 466 501 33.6 % 20.7 % 
 
The durability of coil occlusion of intracranial aneurysms is thought to depend on density 
of packing (volume embolization ratio) achieved within the aneurysm sac.198,269,271 Although 
initial angiographic occlusion may be suboptimal for determining aneurysm recurrence 
after embolization, measurement of volume embolization ratio (calculated by dividing the 
volume of the embolized coils by the volume of the aneurysm) is useful in predicting 
angiographic changes of embolized aneurysms. In the calculation of volume embolization 
ratio coils are considered to be long cylinders (i.e. volume of coil = π x [diameter of coil / 2]2 
x length of coil) and the aneurysm sac is assumed to be an ellipsoid (i.e. volume of 
aneurysm = 4π / 3 x [aneurysm width / 2]2 x [aneurysm length / 2]2 x [aneurysm height 
/ 2]2). High volume embolization ratio (and low risk of recanalization) is usually easier to 
achieve in small aneurysms with a narrow neck than in larger, wide-necked aneurysms.269-
271 
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3  Aims of the study 
The purpose of this study was  
 
 
I To evaluate the safety and efficacy of stent-assisted embolization of ruptured 
wide-necked intracranial aneurysms in the acute phase (<72 h) of SAH. 
 
 
II To assess the usability and efficacy of stent-assisted embolization in the treatment 
of recurrent or residual intracranial aneurysms. 
 
 
III To evaluate the usability of flow-diverting stents in the treatment of complex 
intracranial aneurysms. 
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4  Materials and methods 
4.1  PATIENT SELECTION AND ANEURYSM CHARACTERISTICS 
A retrospective, observational cohort design was adopted in all of the studies [I-III]. The 
study population consisted of all of the patients treated either with stent-assisted 
embolization or with a flow-diverting stent in three tertiary care centers in Finland (Kuopio 
University Hospital, Tampere University Hospital, and Turku University Hospital) during 
the study period. The treated aneurysms were either wide-necked (width of the neck 
≥4 mm or dome-to-neck ratio ≤2; [I-II]) or otherwise complex aneurysms or focal vascular 
pathologies [III] not eligible for conventional or balloon-assisted embolization therapy (Fig. 
6). The form of treatment of the aneurysm was individually evaluated via a consensus 
between an experienced neurosurgeon and an interventional radiologist or 
neuroradiologist. The estimated risks of various retreatment options were weighed against 
the estimated risk of aneurysm rupture, and the patients were informed about the 
treatment options and their estimated risks.  
STUDY POPULATION II:
Patients retreated with stent-
assisted embolization (n = 59)
Estimated # of patients treated with
endovascular techniques (n ~ 890)
Estimated number of patients with intracranial aneurysms
treated between February 2003 and Nov. 2007 (n ~ 2300)
Estimated number of patients with intracranial aneurysms
treated between October 1997 and July 2008 (n ~ 4300)
Estimated # of patients necessitating 
retreatment (n ~ 380)
STUDY POPULATION I:
Patients treated with stent-assisted 
embolization in acute SAH (n = 61)
Estimated number of patients with intracranial aneurysms
treated between March 2009 and October 2010 (n ~ 530)
Estimated # of patients treated with
endovascular techniques (n ~ 210)
STUDY POPULATION III:
Patients treated with a flow-
diverting stent (n = 24)
 
Figure 6. Patient selection flowchart. 
4.1.1  Stent-assisted embolization of ruptured aneurysms in acute SAH [I] 
All patients with ruptured wide-necked cerebral aneurysms who were treated with stent-
assisted coil embolization in the acute phase (<72 hours) of SAH in three tertiary care 
centers (Kuopio University Hospital, Tampere University Hospital, and Turku University 
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Hospital) during the study period (February 2003 to November 2007) were included in the 
study. The retrospective evaluation of the patient records and all angiographic data was 
finished in June, 2008. The study population consisted of 20 men and 41 women with a 
mean age of 55.1 years (range 26–83 years), including five patients (8 %) in whom the 
procedure was unsuccessful due to the difficult target anatomy and tortuosity of the 
arteries. 
Endovascular treatment was often favored over surgical ligation in older patients and in 
patients with poor clinical condition, although in comatose or moribund patients some 
signs of clinical recovery were expected before initiating active endovascular treatments. 
Surgical treatment, on the other hand, was often preferred for young patients with anterior 
circulation aneurysms, or if the patient presented with a large parenchymal hematoma. All 
of the treated aneurysms had a wide-necked profile (i.e. neck width of more than 4 mm or 
dome-to-neck ratio of less than 2). A slight majority of the aneurysms (33 of 61; 54 %) were 
located in the posterior circulation, and two (3 %) of the ruptured aneurysms located in the 
vertebral artery were considered to be dissecting aneurysms. The largest diameter of the 
treated aneurysm ranged from 2 mm to 19 mm (mean 6.7 mm), and none of the ruptured 
aneurysms in this series had been previously treated. 
Technical success of the procedure was recorded if the ruptured aneurysm was 
successfully stented and embolized with a satisfactory angiographic result (complete 
[>95 %] angiographic occlusion or a small neck remnant with angiographic occlusion rate of 
>80 % and contrast medium filling only the neck area of the aneurysm). 
4.1.2  Stent-assisted embolization of recurrent or residual cerebral aneurysms [II] 
The patient records and angiographic data for all consecutive patients with recurrent or 
residual cerebral aneurysms treated with stent-assisted coil embolization in three tertiary 
care centers in Finland (Kuopio University Hospital, Tampere University Hospital, and 
Turku University Hospital) from February 2003 to June 2011 were retrospectively analyzed. 
A total of 59 patients with 60 treated aneurysms were identified, of whom four patients 
treated either in the acute phase (≤72 h; N=2) or late subacute stage (<4 weeks; N=2) of SAH 
were excluded, resulting in a study group of 55 patients with 56 aneurysms (17 men and 38 
women; mean age 51.5 years). The aneurysms included in the study had been initially 
treated either by coil embolization (51 of 56; 91 %) or surgical ligation (5 of 56; 9 %) between 
October 1997 and July 2008. 
Unstable recurrent aneurysms with designated growth of the recurrence size during 
follow-up were typically selected for retreatment, and previously ruptured aneurysms 
were more likely retreated than nonruptured aneurysms. Aneurysm recurrences less than 
2 mm in diameter were not retreated due to the low risk on rebleeding and the difficulty of 
the reembolization procedure, whereas recurrences exceeding 4 mm in diameter were 
usually selected for retreatment although the size of recurrence necessitating retreatment 
depended considerably on the size and shape of the initial aneurysm. The largest diameter 
of the recurrent or residual portion of the aneurysm varied from 2 mm to 20 mm (mean 
5.5 mm) in this series while the largest diameter of the entire aneurysm ranged from 4 mm 
to 27 mm (mean 10.4 mm). Most of the patients (45 of 55; 82 %) had a history of SAH, the 
time interval between SAH and stent-assisted embolization of the aneurysm varied from 
eight weeks to over 10 years.  
Technical success of the procedure was recorded if the recurrent or residual aneurysm 
was successfully stented and re-embolized with a satisfactory initial angiographic result 
with either complete occlusion or a small residual neck. The angiographic results were 
categorized into primary angiographic success (adequate occlusion and stability of the 
stented aneurysm without additional therapies), secondary angiographic success (adequate 
occlusion and stability of the aneurysm achieved by additional therapies), and 
angiographic failure (residual aneurysm and/or instability of the treated aneurysm).   
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4.1.3  Flow-diverting stents in the treatment of complex intracranial aneurysms [III] 
Technical results and follow-up data on 24 consecutive patients (20 female and four male, 
with a mean age of 55.3 years [range 43–70 years]) treated with 29 flow-diverting stents in 
two tertiary care centers (Kuopio University Hospital and Tampere University Hospital) 
between March 2009 and October 2010 were retrospectively evaluated. Stented vascular 
pathologies included diffuse fusiform aneurysms (4 of 24; 17 %), neck remnants of 
previously treated aneurysms (10 of 24; 42 %), wide-necked saccular aneurysms (6 of 24; 
25 %), and multianeurysm complexes (4 of 24; 17 %). The stent placement was performed in 
two patients (8 %) in the acute phase (<72 hours) of SAH, in two patients (8 %) in the 
subacute phase (3–7 days) of SAH, and in addition, 6 of the 20 electively treated patients 
had a previous history of SAH.  
Treatment with a flow-diverting stent was selected only if surgical ligation, sacrifice of 
the parent artery, and endovascular embolization of the aneurysm were considered 
infeasible due to the difficult location and/or morphology of the aneurysm. 
Technical success of the procedure was analyzed by evaluating the delivery of the flow-
diverting stent to the intended vascular pathology, the patency of the parent artery after 
stent insertion, and possible adjunctive therapies. Primary technical success was recorded if 
the flow-diverting device was successfully and without complications delivered across the 
neck of the aneurysm with a fully patent and unobstructed parent artery, while assisted 
primary technical success was recorded if delivery of the stent and unobstructed parent 
artery were achieved with adjunctive medical therapies (ie. peri-interventional balloon 
angioplasty, delivery of additional stents, or medical treatment of perioperative 
thromboembolic events).    
4.2  ENDOVASCULAR PROCEDURE 
4.2.1  Conventional stent-assisted embolization [I-II] 
A 90-cm guiding catheter (Boston Scientific, Fremont, CA, USA) was inserted to the 
relevant carotid or vertebral artery and a microcatheter (Excelsior SL-10; Boston 
Scientific/Target Therapeutics, Fremont, CA, USA) was navigated past the aneurysm with 
the help of a standard micro guidewire. After the deployment of the stent (Neuroform; 
Boston Scientific/Target Therapeutics), the aneurysm was usually embolized with the 
microcatheter placed through the stent interstices, although in a few cases the microcatheter 
was positioned (‘jailed’) in the aneurysm before stent deployment. After stenting, the 
recurrent or residual aneurysms were packed with GDCs and/or Matrix coils (Boston 
Scientific) in earlier phase of the studies and with Target (Stryker Neurovascular, Fremont, 
CA, USA) or Axium coils (ev3 Neurovascular, Irvine, CA, USA) in later cases. The 
Neuroform stent used exclusively in the original communications I and II is a laser cut 
nitinol stent with a semi-open cell structure. 
All of the patients treated in the acute phase of SAH were heparinized (Heparin LEO; 
Leo Pharma, Ballerup, Denmark) during the procedure, with the aim of achieving 
measured activated clotting times (ACTs) of about 250 seconds. The heparinization was 
usually initiated after the first coil or coils had been deployed and the ruptured aneurysm 
was considered to be stable. Intravenous acetylsalicylic acid (250–500mg) was administered 
perioperatively to a majority of the patients (43 of 61; 70 %), and a combination therapy 
with clopidogrel bisulphate (Plavix; Sanofi Pharma Bristol-Meyers Squibb, Paris, France), 
with a loading nose of 300 mg and a daily dose of 75 mg for 1–3 months postoperatively 
and acetylsalicylic acid (100 mg daily for 3–6 months) was started immediately after the 
procedure. 
In the electively treated patients, the dual antiplatelet therapy with clopidogrel 
bisulphate (75 mg daily) and acetylsalicylic acid (100 mg daily) was initiated prior to the 
procedure. Response to clopidogrel bisulphate was confirmed via the VerifyNow system 
(Accumetrics, San Diego, CA, USA) after this device became available in our centers in 
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January 2010 and additional doses of clopidogrel bisulphate or prasugrel hydrochloride 
(Efient; Eli Lilly Nederland BV, RA Houten, The Netherlands) were administered when 
necessary.  All of the patients were periprocedurally heparinized with an ACT target of 
about 240 seconds and dual antiplatelet therapy with clopidogrel bisulphate (75 mg daily 
for 3 months) and acetylsalicylic acid (100 mg daily for a minimum of 6 months) was 
continued postprocedurally. 
4.2.2  Endovascular procedure with a flow-diverting device [III] 
A microcatheter with an inner diameter of 0.60 mm (Vasco + 21 MP; Balt Extrusion, 
Montmorency, France) was navigated past the aneurysm neck the help of a microguidewire 
(Transend EX or Synchro2 Standard; Boston Scientific, Fremont, CA, USA) and a 6F Envoy 
guiding catheter (Cordis Neurovascular; Miami Lakes, FL, USA). The flow-diverting stent 
(Silk; Balt Extrusion, Montmorency, France), which is composed of 48 nickel-titanium 
(nitinol) alloy and platinum filaments that provide a metal to surface area coverage of 
~35 %, was thereafter deployed over the intended vascular pathology with a combination of 
careful pressure on the delivery wire and retraction of the microcatheter. The stent was 
carefully manipulated to achieve full opening and the stent was usually recrossed with the 
delivery catheter after deployment to ensure adequate wall apposition as recommended by 
the manufacturer. In four (17 %) of the later cases, the aneurysm was loosely packed with 
GDCs before stenting.  
4.3  FOLLOW-UP 
Follow-up imaging was primarily performed by DSA. In addition, MR angiography 
(contrast enhanced and three dimensional time-of-flight MR angiography) was occasionally 
utilized in studies I and II if the initial angiographic result was adequate and the risk of 
aneurysm recurrence was small, or if adequate angiographic result and stability of the 
treated aneurysm had already been confirmed in preceding DSA follow-up images. The 
small imaging artifacts caused by the markers at both ends of the Neuroform stent only 
rarely interfered with the interpretation of the MR angiograms.276-280 
4.4  STATISTICAL METHODS 
The statistical analysis was performed with IBM SPSS Statistics (SPSS Inc., Chicago, IL, 
USA). Dichotomous and other categorical variables were compared with the χ2 test or 
Fisher’s exact test, and the Mann-Whitney U test and Kruskal-Wallis one-way analysis were 
used to compare continuous-scale data for non-normally distributed variables [I-III]. 
Continuous-scale data was also frequently categorized to subgroups to facilitate statistical 
analyses. In the original communication III, a binomial regression analysis was also 
performed after univariate analyses. P value of less than .05 was usually considered to 
indicate a statistically significant difference. 
4.5  ETHICAL ISSUES 
The present study was approved by the institutional review board of Tampere University 
Hospital. Due to the retrospective nature of the study, the need to obtain informed consent 
was waived.   
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5  Results 
5.1  STENT-ASSISTED EMBOLIZATION IN ACUTE SAH [I] 
5.1.1  Technical success and initial angiographic results 
The technical success rate was 72 % (44 of 61 patients), and an adequate primary 
angiographic result with either complete occlusion of the aneurysm or a small neck 
remnant was achieved in 64 % (39 of 61 patients) (Fig. 7). In six (10 %) patients, the delivery 
of the stent failed due to the excessive tortuosity of the target artery. After stent 
deployment, coiling of the stented aneurysm was in addition unsuccessful in three (5 %) 
patients due to the small size of the aneurysm (dome height, 2 mm) and in two (3 %) 
patients because of unfavorable anatomy of the aneurysm.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. A DSA image of a wide-necked ruptured basilar tip aneurysm before (a) and after (b) 
stent-assisted embolization of the aneurysm. A complete occlusion of the aneurysm was 
achieved in this case. The proximal and distal markers of the stent (Neuroform 3.5/15 mm) are 
indicated by arrowheads. 
5.1.2  Complications 
Procedure-related major complications were encountered in 13 of the 61 patients (21 %). 
The major complications included aneurysm perforation in four (7 %) patients, 
thromboembolic events in seven (11 %) patients, one case of early rebleeding from the 
aneurysm combined with vasospasm, and one puncture site pseudoaneurysm which was 
successfully treated with US-guided thrombin injection. Periprocedural thromboembolic 
complications were routinely treated with intraarterial abciximab (ReoPro; Contocor, 
ba 
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Leiden, The Netherlands) together with heparin and five of the seven patients with 
thromboembolic events had adequate recovery with GOS scores of 4–5 at the end of the 
study period.  
5.1.3  Follow-up data and clinical outcome 
The mean duration of angiographic follow-up was 12.1 months with a range from 0 to 52 
months. Reembolization of the stented aneurysm was performed in four patients (7 %), 
either due to initial suboptimal occlusion of the stented aneurysm (N=1; 2 %), or due to coil 
compaction and recanalization of the treated aneurysm (N=3; 5 %). The total mortality rate 
was 21 % (13 of 61 patients), with 30-day mortality rate of 20 % (12 of 61). This large 
perioperative mortality rate is partially explained by the poor preoperative clinical 
condition of some of the patients and severe nature of aneurysmal SAH. After the primary 
phase the risk of mortality and morbidity decreased considerably, and most of the patients 
made good recoveries with 42 of the 61 patients having a Glasgow Outcome Scale score of 4 
or 5 at the end of the study period. Patient demographic data, aneurysm characteristics, or 
primary angiographic result did not significantly correlate with the clinical outcome. 
5.2  STENT-ASSISTED EMBOLIZATION OF RECURRENT OR RESIDUAL 
ANEURYSMS [II] 
5.2.1  Technical success  
The technical success rate was 91 % (50 of 55 patients). In one patient (2 %), the delivery of 
the intracranial stent failed due to tortuosity of target artery, and in four patients (7 %) 
adequate coil embolization was not achieved after stenting. 
5.2.2  Adjunctive therapies and procedural complications 
Complications were encountered in six patients (11 %), including perioperative aneurysm 
perforation in three patients (5 %), progressive brain stem compression symptoms after the 
embolization of a large basilar tip aneurysm in two patients (4 %) (Fig. 8), and 
postoperative retroperitoneal and intra-abdominal hemorrhage in one patient (2 %). 
Complications resulted mainly in unfavorable clinical outcome and only the patient with 
retroperitoneal and intra-abdominal hemorrhage recovered without clinical sequelae.  
In addition to procedural complications, periprocedural adjunctive therapies were 
required in five patients including the treatment of minor periprocedural 
thromboembolism with intra-arterial abciximab in two patients (4 %), stenting of 
presumable iatrogenic vertebral dissections in two patients (4 %), and insertion of an 
additional intracranial stent due to suboptimal placement of the primary stent in one 
patient (2 %). None of these five patients had post-procedural clinical sequelae.  
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Figure 8. A marked recanalization is observed in a DSA image (a) obtained 30 months after 
stent-assisted re-embolization of a giant basilar tip aneurysm. In spite of five successive 
endovascular treatment attempts, permanent occlusion of the recurrent aneurysm was not 
achieved and the patient developed brain stem compression symptoms as seen in a T1-
weighted MRI image (b); the patient died within one month. 
5.2.3  Follow-up data and clinical outcome 
Angiographic and clinical follow-up data were available for 51 patients with 52 aneurysms 
(93 %), with a mean follow-up time of 28.1 months (range 3–114 months). Additional 
endovascular treatment sessions were performed in nine patients (16 %), either due to coil 
compaction and recanalization of the recurrent aneurysm (N=7; 13 %) or due to suboptimal 
initial occlusion of the treated aneurysm (N=2; 4 %).  
The clinical outcome was favorable in 50 of 55 patients (91 %), while poor clinical 
outcome was recorded in five (9 %) patients. Perioperative mortality rate was 2 % (N=1). 
Statistically significant correlations were found between poor clinical outcome and giant 
(>25 mm) total aneurysm size (P=0.002), a large (>10 mm) recurrent aneurysm size 
(P=0.011), and the occurrence of periprocedural complications (P<0.001) (Table 6). Since 
there was a strong intercorrelation between recurrence size and total aneurysm size 
(P=0.006) in a binomial regression analysis, the only independent factor related to poor 
clinical outcome was the occurrence of periprocedural complications (P=0.017). 
 
 
 
 
 
 
 
a b
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Table 6. Factors associated with clinical outcome after stent-assisted embolization of recurrent 
or residual aneurysms. 
 
 P valuea 
Total aneurysm size 0.002 
Recurrent/residual aneurysm size 0.011 
The occurrence of periprocedural complications <0.001 
Administration of adjunctive medical therapy 1.000 
Initial post-operative angiographic result (complete occlusion; neck remnant; 
partial occlusion / no coiling) 
0.669 
Number of previous treatment sessions (1; 2-4; ≥5) 0.104 
History of SAH  1.000 
5.3  FLOW-DIVERTING STENTS IN THE TREATMENT OF COMPLEX 
CEREBRAL ANEURYSMS [III] 
5.3.1  Technical success  
The primary technical success of the procedure was 67 % (16 of 24 patients). In addition, 
assisted primary technical success was recorded in five patients (21 %). Technical failure 
was recorded in three patients (13 %): the flow-diverting stent could not be deployed due to 
difficult target vessel anatomy in one patient (4 %); the stent remained partially tapered 
regardless of balloon angioplasty in one patient (4 %); and a delayed major ischemic 
complication was encountered in one patient (4 %) and was regarded as a technical failure 
although the initial angiographic result was desirable. 
5.3.2  Complications and periprocedural adjunctive therapies 
Periprocedural adjunctive therapies were administered in six patients (25 %), including 
three (13 %) cases where additional balloon angioplasty was required to open the flow-
diverting stent fully and 1 case (4 %) where a closed-cell stent (Enterprise; Cordis 
Endovascular, Miami Lakes, FL, USA) was placed inside the flow-diverting stent to ensure 
the patency of the device. In two of these cases, the transitory flow obstruction caused by 
the incompletely opened flow-diverting stent resulted in thromboembolism necessitating 
administration of intra-arterial abciximab (ReoPro; Contocor, Leiden, The Netherlands). 
Altogether, periprocedural thromboembolism was treated with intra-arterial abciximab in 
four patients (17 %), none of whom developed permanent neurological sequelae. 
Procedural complication and mortality rates were 4 % (1 of 24; a fatal ischemic stroke 
within 24 hours from the procedure). 
5.3.3  Follow-up data and clinical outcome 
Follow-up data was available for twenty patients (83 %; 23 aneurysms and 24 stents), with a 
mean angiographic follow-up time of 9.0 months (range 2–17 months). Complete occlusion 
of the stented aneurysm was observed in 16 of 23 stented aneurysms in 16 patients (70 % 
and 80 %, respectively) (Fig. 9). In four aneurysms (17 %), the flow-diverting stent had not 
induced thrombosis and the aneurysms remained unsecured. Follow-up of these patients is 
continuing and further treatment options will be individually considered based on the 
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longer term follow-up images. In addition, follow-up imaging revealed asymptomatic 
stenosis (N=1) and occlusion (N=1) of the stented artery in two patients (10 %). 
The clinical outcome was favorable in majority of the patients, with a GOS score of 4 or 5 
in 22 of 24 patients (92 %) at the end of the study period. A GOS score of 3 was recorded in 
one (4 %) patient and a GOS score of 1 in one (4 %) patient, both of whom were in the acute 
or subacute SAH group. There was a statistically significant correlation with poor clinical 
outcome and acute or subacute SAH (P=0.022; Fisher’s exact test), but statistical analyses 
were subsequently removed due to the small amount of patients in the (sub)acute SAH 
group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. A large basilar tip aneurysm was treated with a flow-diverting stent (Silk 3.5/25 mm) 
which is well visible in a perioperative DSA image (a). Note the stasis of the contrast material 
within the aneurysm sac indicating the hemodynamic changes induced by the stent. Occlusion 
of the aneurysm and patency of the parent vessel may be assessed in a follow-up TOF-MRA 
image acquired at six months (b), although a slight narrowing of the stented segment (indicated 
by arrowheads) is induced by the ferromagnetic bands of the stent. 
a b
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6  Discussion 
The rapid development of intracranial stents has revolutionized the management of 
intracranial aneurysms and has enabled the treatment of many previously untreatable 
cerebral aneurysms. However, many limitations and challenges still persist, and stent-
assisted embolization is far from being a panacea in the treatment of complex intracranial 
aneurysms. Due to the lack of long-term knowledge on the risks of arterial injury or 
stenosis after stent deployment, aneurysm recurrence, or even the risk of stent fracture, all 
intracranial stents should be used very selectively on younger patients with a substantial 
life expectancy.180 The complications and adverse outcomes encountered in this study 
emphasize the relevance of the operator’s expertise, the importance of adequate 
antithrombotic medical therapy, and the pivotal role of proper patient selection. It is also 
worth noticing that the retrospective study cohorts presented in this study consist of first 
generation stents and flow diverting devices at the earliest phase of the learning curve. 
As stated in an excellent review on treatment strategies for complex intracranial 
aneurysms, perhaps the most significant breakthrough in the management of complex 
intracranial aneurysms in recent years has been the complementary interaction of 
endovascular and surgical technologies and the waning of the coil versus clip controversy.7 
Optimal treatment of cerebral aneurysms requires the availability of both experienced 
cerebrovascular surgeons and interventional neuroradiologists working in a collaborative 
effort to tailor an individual treatment plan for each patient. In addition, acute aSAH is a 
complex and multifaceted disorder and many of the aSAH patients require a prolonged 
treatment in the intensive care unit. The management of aSAH patients focuses also on the 
anticipation, prevention and management of secondary complications (i.e. rebleeding from 
the aneurysm, hydrocephalus, seizures, cardiopulmonary complications, and delayed 
cerebral ischemia), and favourable outcomes are more likely in institutions that treat high 
volumes of patients with aneurysmal SAH.  
6.1  DISADVANTAGES OF ENDOVASCULAR ANEURYSM THERAPY  
In addition to the technique-related limitations of endovascular treatment methods 
discussed in detail in Chapter 2, there are several additional perspectives that should be 
considered when evaluating endovascular techniques against microsurgical aneurysm 
therapy. Firstly, the cost of novel endovascular devices exceeds vastly the cost of 
microsurgical clips. While the price of a microsurgical clip is usually at most a few hundred 
euros, all of the intracranial stents are priced in several thousand euros and the price of 
flow-diverting devices often exceeds 10 000 euros. It remains to be seen whether the price of 
endovascular devices will eventually drop when the number of manufacturers increases 
and the market becomes saturated. 
Secondly, the use of intracranial stents necessitates antithrombotic medication. The 
guidelines for antiplatelet therapy after stent-assisted embolization are based on cardiology 
experience, and recent cardiology guidelines recommend administration of acetylsalicylic 
acid indefinitely after coronary stenting, whereas clopidogrel bisulphate is usually 
administered for 12 months.281 In intracranial stents, however, aneurysmal factors should 
also be considered. Incomplete aneurysm occlusion may produce a dead space in 
combination with the stent, resulting in continual flow disturbance and becoming a long-
term embolic source. Delayed ischemic stroke after stent-assisted embolization seems to be 
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associated mainly with insufficient duration of dual antiplatelet therapy rather than 
inadequate platelet inhibition.282 While short-term combination therapy of clopidogrel 
bisulphate and acetylsalicylic acid is effective and safe for stroke prevention even in high 
vascular risk patients, long-term combination therapy increases the risk of intracranial 
hemorrhage and major bleeding substantially.283-285 Therefore, the duration of dual 
antiplatelet therapy should probably be tailored to clinical status, co-morbidities, and 
angiographic outcome of each patient. 
Thirdly, endovascular aneurysm treatment almost invariably necessitates long-term 
angiographic follow-up. Aneurysm recurrence is common after coil embolization (see 
paragraph 2.5), and routine angiographic follow-up imaging for a minimum of three years 
after aneurysm embolization has been recommended.275 It is also worth noticing that there 
is, as yet, no information on long-term or lifetime efficacy and safety of stent-assisted 
embolization, advocating very long clinical and angiographic follow-up after stent-assisted 
aneurysm treatment.   
6.2  STENT-ASSISTED EMBOLIZATION OF ACUTELY RUPTURED WIDE-
NECKED ANEURYSMS [I] 
Early treatment of the ruptured aneurysm is usually well-grounded due to the high risk of 
subsequent rerupture of the aneurysm.85 Acute SAH is, however, a hypercoagulable state in 
which the tendency for thrombosis is high, which correspondingly increases also the risk of 
both perioperative thromboembolic events and the risk of parent vessel occlusion after the 
stent deployment. It may even be argued that stent-assisted aneurysm embolization in 
acute SAH has little in common with stent-assisted aneurysm embolization in an elective 
setting, and that the use of stent-assisted embolization in the acute SAH remains somewhat 
controversial despite positive results reported in a few limited series.12,286 
In a systematic review of published data on stent-assisted coiling in acutely ruptured 
intracranial aneurysms, it was suggested that adverse outcomes are more common in stent-
assisted coil embolization in acutely ruptured aneurysms compared with similar grade 
acutely ruptured aneurysms treated by coil embolization alone.232 Furthermore, in a recent 
study of 72 patients with ruptured wide-necked aneurysms treated with stent-assisted coil 
embolization in acute SAH, microsurgical clipping or endovascular treatment with another 
technique (i.e. multiple microcatheter or balloon assisted technique) was advocated due to 
the high complication rate (19.4 %; 14 of 72 patients) observed in the study.231 Stenting is, 
however, known to stabilize and improve the anatomical results of coil embolization 
especially in wide-necked aneurysms in which unassisted or even balloon-assisted 
embolization may prove infeasible. The controversial results on stent-assisted embolization 
of acutely ruptured cerebral aneurysms reflect the difficulties encountered in the 
therapeutical decisions in the setting of acute SAH, and the optimal patient selection for 
each treatment method in the acute phase of SAH is still open to discussion.286  
Aggressive periprocedural heparinization and preprocedural dual antiplatelet therapy 
with clopidogrel bisulphate and acetylsalicylic acid routinely administered in the stent-
assisted embolization of nonruptured aneurysms are contraindicated in the setting of acute 
SAH. Heparinization was typically initiated in our study after the first coil or coils had been 
deployed to the aneurysm sac and the ruptured aneurysm was considered to be stable, 
although small amounts of heparin were administered from the beginning of the procedure 
in the continuous rinsing infusion of the catheters. Combination therapy with clopidogrel 
bisulphate and acetylsalicylic acid was started immediately after the procedure. The highly 
operator-dependent delay in the initiation of adequate antithrombotic therapy – in a 
hypercoagulable state with an increased risk of thromboembolism – heightens the 
importance of the smooth, undelayed course of the procedure. In the setting of ruptured 
wide-necked bifurcation aneurysms, treatment with an intrasaccular flow disruption device 
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(WEB) might be feasible since it seems to offer reasonable aneurysm stability and occlusion 
rate without the need for subsequent dual antiplatelet therapy.257 
The complication rate in our study was higher than was reported in several series of 
stent-assisted embolization of wide-necked cerebral aneurysms treated almost invariably in 
an elective setting.9,220-223 Our results are, however not directly comparable to these studies 
because of the excess mortality and morbidity associated with acute SAH. In addition, the 
patient population was highly biased due to the selective nature of our study and difficult-
to-treat posterior fossa aneurysms were markedly over-represented in our series. When 
compared to the baseline results set by the ISAT study, in which 250 of 1063 patients (23.5 
%) with ruptured intracranial aneurysms allocated to endovascular treatment were dead or 
dependent at 1 year, our results are directly comparable with 13 of 61 patients (21.3 %) dead 
or dependent at 12.1 months.153 
6.3  STENT-ASSISTED EMBOLIZATION OF RECURRENT OR RESIDUAL 
CEREBRAL ANEURYSMS [II] 
Coil compaction and aneurysm recurrence after coil embolization is common, with 
reported incidences of up to 33.6 %.202,266,267,287 Additional coiling of previously embolized 
and recanalized aneurysms is safe and leads to sufficient occlusion in most aneurysms.288,289 
Furthermore, the risk of additional coil embolization of recurrent cerebral aneurysms does 
not negate the advantage of the initial embolization and the risks of retreatment may even 
be smaller than those posed by the initial endovascular aneurysm therapy.274,290  
There seems, however, to be a small subgroup of patients with wide-necked aneurysm 
recurrences requiring advanced endovascular therapies and often multiple retreatment 
sessions. Stent-assisted coil embolization is feasible for the retreatment of these challenging 
recurrences with wide-necked profile, but an intracranial stent does not by itself guarantee 
occlusion or stability of the stented aneurysm.8,291 In a large, prospective multicenter study 
of 311 patients with 352 retreatment procedures after aneurysm recurrence, it was observed 
that two of the three treatment-related deaths and the single case of permanent major 
disability occurred in patients who underwent endovascular treatment more than once for 
aneurysm recurrence.290 In another study of 124 recurrent or residual ruptured aneurysms, 
the risk of rebleeding or regrowth of the aneurysm was associated with large aneurysm 
size, aneurysm location in the posterior circulation, and aneurysm re-permeabilization.292  
The results of our study are in agreement with these studies to a large extent. Good 
clinical outcome and permanent occlusion of the recurrent aneurysm were unlikely in our 
series if the aneurysm exceeded 2 cm in diameter (P=0.012), if the recurrent diameter of the 
aneurysm was over 10 mm (P=0.011), or if mass effect was present with a large or giant 
partially thrombosed aneurysm (P=0.007). 
6.4  FLOW-DIVERTING STENTS IN THE TREATMENT OF COMPLEX 
INTRACRANIAL ANEURYSMS [III] 
The initial results published on endoluminal flow-diverting devices (namely the Pipeline 
embolization device, PED) were exceedingly promising with complete angiographic 
occlusion in 94 % of the treated aneurysms with angiographic follow-up at 12 months with 
no major clinical adverse effects periprocedurally or during follow-up.14 However, an 
increasing number of perforating branch strokes, stent thromboses, and parent artery 
stenoses at follow-up were reported in subsequent reports.17,18,293 The experience in using 
flow-diverting stents in the treatment of aneurysms of various sizes and shapes is 
continuously increasing, albeit often only by the method of trial and error, and at times 
with unacceptable complications. While the initial experience with flow-diverting stents 
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was mostly limited to the treatment of aneurysms arising from the ICA, reports of flow-
diverting stents in the treatment of basilar artery aneurysms, ruptured anterior cerebral 
artery aneurysms, and even complex middle cerebral artery aneurysms have now been 
published.294-296 Although flow-diverting stents are associated with undeniable procedural 
risks, they represent a true advancement in the endovascular treatment of complex cerebral 
aneurysms and allow many previously untreatable aneurysms to be successfully managed. 
An intracranial stent is considered to be thrombogenic until the stent has been covered 
by the endothelialisation and the normal intrinsic fibrinolytic activity of the endothelium 
has renewed. It is, however, still unclear what is the duration of this process with flow-
diverting stents, and indeed if it is even possible in the case of multiple overlapping stents 
with a high metal surface coverage. Our results as well as the reported cases of very late in-
stent thrombosis occurring with flow-diverting stents supports the use of prolonged post-
procedural antithrombotic therapy which may, on the other hand hinder the goal of the 
therapy, i.e. occlusion of the stented aneurysm.297,298 The use of a single flow-diverting stent 
should be preferred to using multiple overlapping devices since a single stent may provide 
similar occlusion rates with less complications and better overall outcomes.250 
As discussed previously with conventional intracranial stents, the timing of the 
treatment with a flow-diverting stent is of pivotal importance in the treatment of acutely 
ruptured cerebral aneurysms. Of the four patients who developed periprocedural 
thromboembolism necessitating administration of intra-arterial abciximab, two had either 
acute (N=1) or subacute (N=1) SAH. In addition, the only major complication encountered 
in the series (fatal ischemic stroke within 24 hours of the procedure) was recorded in a 
patient with acute SAH. Thereby, either symptomatic or asymptomatic thromboembolic 
events were encountered in three of the four patients (75 %) treated with a flow-diverting 
stent during acute or subacute SAH while in the electively treated group thromboembolic 
events were encountered in only one patient (5 %).   
In March 2010, the manufacturer of the Silk flow-diverting stent (Balt Extrusion, 
Montmorency, France) released an urgent field safety notice advising to use the Silk stent 
only in adjunct with coil embolization since eight patients treated with a mere Silk stent 
had died of unexpected aneurysm rupture during short- or mid-term follow-up after the 
Silk implantation. Thirteen cases of delayed post-procedural aneurysm rupture in twelve 
different centers were analyzed and it was suggested that intra-aneurysmal thrombus 
formation after flow-diversion treatment of large and giant cerebral aneurysms may trigger 
a complex cascade of biologic events and that autolytic effects of the thrombus may lead to 
delayed rupture of the aneurysm.16 It is known that many of the observed genetic 
alterations associated with aneurysm formation also directly affect the repairing processes 
of the vessel wall (see paragraph 2.1.2). Further knowledge and understanding of the 
biochemical processes behind aneurysm development and rupture could therefore help 
also in the patient selection with flow-diverting stents. The release of this urgent safety field 
notice by the stent manufacturer also reflects the incomplete, yet continuously 
accumulating clinical knowledge of these novel devices.  
Flow-diverting stents offer fascinating opportunities for the treatment of segmentally 
diseased arteries, often collectively entitled as complex aneurysms. There is, however no 
formal or universally accepted definition of a ‘complex’ intracranial aneurysm. The 
following features have been suggested to be commonly associated with complex 
aneurysms: (1) diameter greater than 25 mm; (2) location of difficult access; (3) presence of 
previous treatments; (4) absence of collateral circulation; (5) intraluminal thrombus; (6) 
calcified or otherwise challenging (blister-like, dissecting) aneurysm wall; (7) wide necked 
or otherwise challenging aneurysm configuration; and (8) parent artery or branches arising 
directly from the aneurysm.7,299 Nonetheless, even with the slightly equivocal safety profile 
of flow-diverting devices, treatment of complex intracranial aneurysms with a flow-
diverting stent is justified when conventional endovascular or surgical treatment options 
are not applicable. Clinical data on flow-diverting stents is difficult to obtain due to rarity 
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of applicable aneurysms, but larger studies with long-term follow-up and preferably 
randomized controlled setting are mandatory in evaluating the long-term efficacy and 
safety of these devices.  
6.5  STUDY LIMITATIONS [I-III] 
Possibly the most notable limitation of our study is the selection bias. It has been shown 
that the endovascular treatment decisions vary markedly between centers and individual 
operators and that the interobserver and intraobserver agreement weakens progressively 
with increasing response choices (i.e. treatment options).300,301 The form of treatment for 
each patient was, however, selected based on a consensus between a neurosurgeon and 
interventional radiologist who evaluated the data with similar guidelines.   
Without systematic post-operative MRI studies it is impossible to know the factual 
amount of clinically silent microembolic complications associated with different 
endovascular treatment methods. This is, however, a common phenomenom in this field of 
science. Since aneurysm formation is a dynamic process, even stable and durable 
angiographic results may be altered due to de novo aneurysm formation. Inherent study 
limitations arise also from our study population which consists solely of Finnish patients. 
Since the risk of aneurysm rupture is higher in Finnish and Japanese populations compared 
to other countries, it may be debatable whether the results of our study can be directly 
extrapolated to other countries and/or populations.21,22 
Finally, remarkable inherent study limitations arise from the retrospective setting of this 
study. The first-generation devices utilized in this study have been replaced by more 
advanced devices, and it seems evident that these enhanced devices with easier delivery 
and smaller profile, together with continuously improving microcatheters, guide wires, and 
image guiding technologies will reduce the clinical applicability of the study results by 
further improving the technical success rates and by facilitating the treatment of even more 
peripheral and morphologically challenging aneurysms.   
6.6  FUTURE PERSPECTIVES 
In the field of interventional neuroradiology the ever increasing pace of technological 
development is unparalleled, even in the scope of medicine. The continual and rapid 
advances in material technology and bio-compatible materials, manufacturing processes, 
biotechnology, and nanotechnology will offer new endovascular treatment options at an 
accelerating rate, and the role of intracranial stents is becoming ever more important in the 
management of cerebrovascular diseases. The main focus of aneurysm research and 
treatment will shift further from reactive treatment of aSAH to aneurysm screening and 
prevention of aneurysm rupture. Although novel endovascular treatment options may 
solve some of the challenges involved in the treatment of complex cerebral aneurysms, 
advanced surgical techniques and endovascular procedures will always be complementary. 
Only multidisciplinary team approach allows the successful management of previously 
untreatable cerebral aneurysms – both now and in the future.  
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7  Conclusions 
 
I Stent-assisted coil embolization is a feasible treatment method for the 
endovascular treatment of ruptured wide-necked intracranial aneurysms that are 
difficult to treat with surgical ligation or with balloon-assisted embolization also 
during acute SAH. The risk of subsequent rerupture of the aneurysm seems to be 
reduced for aneurysms treated early compared with that of nonsecured 
aneurysms despite intensified postinterventional antiplatelet therapy, but the 
optimal antiplatelet medication during acute phase treatment is still equivocal 
and a longer follow-up series is needed to evaluate the long-term efficacy and 
safety of stent-assisted coil embolization during acute SAH. 
 
II Stent-assisted coil embolization is beneficial for the treatment of wide-necked 
recurrent or residual aneurysms. Stability and permanent occlusion of the 
recurrent aneurysm is however unlikely if the aneurysm exceeds 2 cm in 
diameter or the largest diameter of the recurrence volume exceeds 10 mm. 
Alternative treatment methods (i.e. parent vessel occlusion, surgical clipping, or 
treatment with a flow-diverting device) may also be preferable if mass effect is 
present with the recurrent aneurysm. 
 
III Many previously untreatable intracranial aneurysms may be successfully treated 
with a flow-diverting stent, but the associated risk of thromboembolic events is 
justifiable only if conventional endovascular or surgical treatment options are not 
applicable. Due to the risk of delayed in-stent thrombosis, meticulous long-term 
clinical and angiographic follow-up is essential after the deployment of a flow-
diverting stent. Perioperative thromboembolic events should be prepared for and 
treated without unnecessary delays, because they seem to frequently respond to 
adjunctive medical therapy. 
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The incidence of aneurysmal subarach-
noid hemorrhage in Finland is among 
the highest in the world, affecting ap-
proximately 1200 patients each year. 
Endovascular treatment of intracranial 
aneurysms is firmly established, but 
endosaccular coil embolization of very 
wide-necked or otherwise complex 
cerebral aneurysms is often technically 
challenging. The development of in-
tracranial stents has revolutionized the 
endovascular management of complex 
intracranial aneurysms and many previ-
ously untreatable cerebral aneurysms 
are now within the scope of endovas-
cular treatment. However, many limita-
tions and challenges still persist and the 
optimal treatment of cerebral aneurysms 
requires complementary interaction of 
surgical and endovascular techniques.
